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Diabetes mellitus is a chronic and global disease rapidly growing in prevalence. Diabetes can be 
characterized by the dysfunction or death of the glucose sensing insulin secreting  cell.  cells 
are located within the islet of Langerhans (islet), a tissue within the pancreas. Human islets are 
critical for the study and treatment of diabetes. However, they can only be obtained from 
cadaveric organ donors. These cadaveric islets do not proliferate and can only be maintained in 
vitro for short periods of time, making their availability rare and fleeting. Stem cell-derived -
like cells can be generated in indefinite amounts and are a potential alternative to cadaveric islet 
cells. Throughout this document stem cell-derived -like cells will be interchangeably referred as 
SC- cells or SC-islet. A major challenge towards applying SC- cells to disease modeling or 
cell replacement therapies is their lack of functional maturity and supporting technology. In this 
thesis, I am to investigate and improve the functional maturity of SC- cells and their supporting 




temporally manipulating TGF signaling, I develop a novel differentiation protocol for 
generation of SC- cells with enhance function. These enhanced SC- cells are generated more 
efficiently and achieve dynamic insulin secretion with first and second phase insulin secretion 
kinetics, a critical hallmark of cadaveric islet function. When transplanted into immune 
compromised diabetic mice, their function is detected within two weeks and cure their diabetes. 
In Chapter 3, I elucidate the role of transcription factor SIX2 in SC- cells differentiations. 
Using gene knockdown and knockout techniques, I show SIX2’s necessity for the functional 
maturation of SC- cells. Importantly, I identify SIX2 positive and negative  cell populations 
and postulate its use as a marker to guide future  cell maturation efforts. In Chapter 4, I present 
a method for cryopreserving SC-islets and characterize them relative to their un-cryopreserved 
counterparts. Cryopreserved SC-islets functionally and transcriptionally resemble un-
cryopreserved SC-islets. This advancement will facilitate biobanking of stem cells, a necessary 
step to increase their accessibility to the research and therapeutic research population.  In 
Appendix A, I describe the application of a luciferase insulin secretion reporter in SC- cells. 
Luciferase co-secretes in correlation with insulin and a proof-of-concept compound screen is 
performed identifying several  cell secretagogues. These secretagogues were then assessed with 
cadaveric islets verifying the potential of SC- cells as biologically relevant screening models. In 
Appendix B, I describe a method for co-culturing SC- cells with endothelial cells using a 
hydrogel system. The work in this thesis advances SC- cell technologies and facilitates their use 
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Human stem cell-derived β (SC-β) cells have the potential to revolutionize diabetes treatment 
through disease modeling, drug screening, and cellular therapy. SC-β cells are likely to represent 
an early clinical translation of differentiated human pluripotent stem cells (hPSC). In 2014, two 
groups generated the first in vitro-differentiated glucose-responsive SC-β cells, but their 
functional maturation at the time was low. This review will discuss recent advances in the 
engineering of SC-β cells to understand and improve SC-β cell differentiation and functional 
maturation, particularly new differentiation strategies achieving dynamic glucose-responsive 
insulin secretion with rapid correction to normoglycemia when transplanted into diabetic mice.  
1.2 Introduction 
 
Diabetes mellitus can be characterized as a disease of the β cell, which results in improper 
insulin secretion and failure to maintain normal glycemia. Type 1 diabetes (T1D) is the result of 
the dysregulated autoimmune destruction of β cells (Gillespie 2006). Type 2 diabetes (T2D) is 




hyperglycemia. Currently T1D and many T2D patients are reliant on exogenous insulin 
treatment. Exogenous insulin treatment requires constant monitoring and injections throughout 
the day, reducing quality of life and failing to accurately maintain normal glycemia leading to 
secondary complications (Caro, Ward, and O’Brien 2002; Powers and D’Alessio 2011). 
Transplantation of whole pancreas or purified islets of Langerhans have been shown to result in 
exogenous insulin independence with accurate glycemic regulation in T1D and T2D patients 
(Gruessner and Gruessner 2016; Kandaswamy et al. 2018; Posselt et al. 2010). Widespread 
application of islet transplantation is limited by replacement tissue availability and the need for 
immunosuppression (Millman and Pagliuca 2017a). 
Human SC-β cells are a promising alternative cell source for diabetes cell replacement therapy as 
well as disease modeling and drug screening (Millman and Pagliuca 2017a). In 
vitro differentiated SC-β cells were first produced in 2014 (Pagliuca et al. 2014; Rezania et al. 
2014). These early SC-β cells presented β cell hallmarks, such as insulin secretion in response to 
glucose, expression of β cell transcription factors, and in vivo function in weeks after 
transplantation in mice. However, critical differences remained between SC-β cells and primary 
adult β cells, including inferior insulin secretion per cell, dysregulated glucose-stimulated insulin 
secretion (GSIS) dynamics, and lower expression of key β cell transcription factors. Recent 
studies, discussed here, have significantly advanced the functional maturity of SC-β cells 
resulting in functionally enhanced SC-β cells. These enhanced SC-β cells have improved 
function, with some achieving dynamic insulin secretion marked by the presence of first and 
second phase insulin secretion. Despite the enhancement of these SC-β cells, they fail to match 
the glucose responsiveness and transcriptomic profile of primary cadaveric islets (Baron et al. 




2019b). In this review we describe the advancements made for achieving enhanced SC-β cells 
and the path toward differentiating fully functional SC-β cells resembling cadaveric islets in 
terms of their function and transcriptomic profile.  
1.3 The Path Toward SC-β Cells 
 
The path toward differentiating SC-β cells has proved challenging, having already spanned over 
two decades. Progress has occurred in waives as hard-fought milestones are achieved. Early 
pioneering work established methodologies for differentiating hPSCs toward definitive 
endoderm (Kevin A D’Amour et al. 2005), the first developmental stage in the path toward 
making β cells. Further sequential treatments of growth factors and small molecules continued to 
mimic pancreatic organogenesis guiding hPSCs through stages resembling definitive endoderm, 
gut-tube endoderm, pancreatic endoderm, and ultimately hormone expressing endoderm. The 
resulting insulin producing cells were polyhormonal, failed to maintain PDX1 and NKX6.1 
expression, and were not glucose responsive (Amour et al. 2006). However, transplantation of 
hPSC-derived pancreatic progenitors into immunocompromised mice allowed for their 
differentiation into monohormonal glucose-stimulated insulin-secreting cells after several 
months in vivo (E Kroon et al. 2008; Rezania et al. 2012). Since then, other groups have 
demonstrated that PDX1 and NKX6.1 expressing pancreatic progenitors have the potential of 
differentiating toward β cells (Millman et al. 2016; Nostro et al. 2015; Rezania et al. 2013; 
Schaffer et al. 2013). 
In 2014, two protocols were published for the efficient generation of glucose-responsive 
monohormonal in vitro-differentiated SC-β cells (Pagliuca et al. 2014; Rezania et al. 2014). 
These protocols generated pancreatic progenitors with high PDX1, NKX6.1 and low NGN3 




progenitors from earlier protocols (E Kroon et al. 2008; Rezania et al. 2012). These pancreatic 
progenitors where then differentiated to hormone expressing endocrine cells through transient 
NGN3 upregulation by treatment with TGFβR1 inhibitor ALK5i Type II (ALK5i) and thyroid 
hormone (T3). Air-liquid interface culture was observed to increase NGN3 expression relative to 
planar culture (Rezania et al. 2014) while the other protocol was completed in suspension culture 
(Pagliuca et al. 2014). The continued treatment of endocrine CHGA+ cells with ALK5i, T3, and 
γ-secretase (XXI or XX) drives the endocrine population toward monohormonal INS+ cells. The 
final stage of these protocols cultured the cells with ALK5i and T3 resulting in glucose 
responsive SC-β cells making up ∼40% of the population. In addition to ALK5i and T3, Rezania 
includes compounds R428, an AXL inhibitor, with N-acetyl cysteine, claiming them to drive 
expression of β cell maturation gene MAFA. The Rezania et al. air-liquid interface culture 
format can be more easily replicated by laboratories with standard culture experience and 
equipment, however it is less scalable than the suspension culture format described in Pagliuca et 
al. which requires more specialized equipment and knowledge of 3D cell culture. These original 
SC-β cells represented a monumental accomplishment being scalable, glucose responsive, 
transcriptionally similar to primary islets, and capable of regulating mouse blood glucose in 
weeks post transplantation. Despite these accomplishments the resulting SC-β cells were 
functionally immature, secreting low levels of insulin, no dynamic insulin secretion, immature 
calcium response, and transcriptional differences remained relative to cadaveric islets with 
measurable differences in MAFA, UCN3, and GCK gene expression (Pagliuca et al. 2014; 
Rezania et al. 2014). 





Early SC-β cells are functionally immature lacking dynamic insulin secretion and observable 
functional maturation occurring after transplantation in vivo, marked by an increase in secreted 
insulin with time post transplantation (Pagliuca et al. 2014; Rezania et al. 2014; Russ et al. 
2015). More functional SC-β cells are needed to improve cell replacement outcomes and 
facilitate more robust disease modeling studies. Recent publications have demonstrated 
improved differentiation efficiency, higher glucose stimulated insulin secretion, first and second 
phase insulin secretion, response to multiple secretagogues, and fast in vivo glucose regulation 
upon transplantation (Table 1.1) (Hogrebe et al. 2020; Mahaddalkar et al. 2020; Nair et al. 2019; 
Velazco-Cruz et al. 2019b; Veres et al. 2019). 
Velazco-Cruz et al. was first to report robust dynamic insulin secretion of SC-β cells (Velazco-
Cruz et al. 2019b) with both first and second phase kinetics using a suspension differentiation 
protocol with temporal TGFβ modulation, cellular cluster size control, serum free media, 
endocrine enrichment without cell selection, and a simplified final stage media lacking notable 
prior factors (T3, N-acetyl cysteine, Trolox, and R428). The authors show that treatment with 
TGFβR1 inhibitor, ALK5 inhibitor type II (ALK5i), is necessary for specification of the β cell 
fate. However, upon β cell specification permittance of TGFβ signaling is critical for SC-β cell 
functional maturation. However, ALK5i is widely used in the final stage of many β cell 
differentiation protocols (Pagliuca et al. 2014). The authors show that by re-sizing cellular 
clusters during the last stage of the differentiation, a process which involves partial dissociation 
of clusters as previously reported (Song and Millman 2017), enhances static GSIS and nearly 
doubles the C-Peptide+ NKX6.1+ co-expressing SC-β cell population. In dynamic secretion 
assays, robust dynamic function with a clear first phase, stable second phase, and a return to 




that insulin secretion per cell and the degree insulin secretion was increased in response to high 
glucose varied across different hPSC lines. Transplantation of these cells improved glucose 
tolerance in mice. 
Veres et al. employed some of the same changes as Velazco-Cruz et al., including cellular cluster 
size control, serum free media, endocrine enrichment without cell selection, and a final stage 
media lacking T3, N-acetyl cysteine, Trolox, and R428 (Veres et al. 2019). Additionally, Veres 
et al. employs β cell enrichment using cell sorting. Through a similar cellular reaggregation 
method, Veres et al. sees strong endocrine enrichment and an increase in the frequency of the C-
Peptide+ /NKX6.1+ SC-β cell population along with improved static GSIS. The authors further 
show that enrichment of the β cell population through CD49a+ cell sorting improved static GSIS 
relative to unsorted and reaggregated SC-β cells. CD49a+ sorted cells demonstrated first and 
second phase insulin secretion, however a return to basal levels did not occur when high glucose 
was removed. The authors did not show if reaggregated cells could undergo dynamic GSIS. The 
authors identify enterochromaffin-like cells in their SC-β cell preps and CD49+ sorting removes 
these cell types. Enterochromaffin cells, marked by TPH1 expression, secrete serotonin in the gut 
and are absent from the human pancreas. This study indicates β cells and enterochromaffin cells 
share a similar developmental path resulting in their presence in β cell differentiation protocols. 
It is unclear if the functional benefits observed by CD49+ sorting are due to the removal of off 
target cell types, such as enterochromaffin-like cells, or other mechanisms. Transplantation into 
mice was not investigated in this study. 
In a separate study, Nair et al. achieved first phase insulin secretion using an insulin-driven GFP 
tag cell sorting approach and a reaggregation process (Nair et al. 2019). The authors achieved a 




authors compare reaggregated GFP enriched cells to un-reaggregated unsorted β cell clusters, 
with limited functional studies using reaggregated and unsorted clusters as a control. The authors 
see no first phase response in the immature clusters or the reaggregated and unsorted clusters 
while there GFP sorted reaggregated clusters have a first phase stimulation index of ∼3 and no 
second phase response. However, the study design did not allow for distinguishing functional 
improvements related to endocrine enrichment by reaggregation or β cell enrichment by sorting, 
like done with CD49a enrichment (Veres et al. 2019). This study was performed using only one 
insulin-driven GFP reporter cell line, making it unclear how well this approach would apply to 
other cell lines and whether the low levels of insulin secretion are due to the genetic engineering 
or genetic background of this cell line relative to other protocols. It is important to note that this 
differentiation protocol retains ALK5i and T3 during the final stage of differentiation, while 
other enhanced SC-β cell protocols have removed them (Hogrebe et al. 2020; Maxwell et al. 
2020a; Rosado-Olivieri et al. 2019; Velazco-Cruz et al. 2019b; Veres et al. 2019). Therefore, it is 
possible that removal of these compound will allow for more robust dynamic secretion including 
the missing second phase observed by this protocol. Transplantation of these cells improved 
glucose tolerance in mice. 
Hogrebe et al.,2020 used a different differentiation strategy for generating SC-β cells, 
demonstrating that regulation of actin cytoskeleton polymerization controls differentiation to 
endocrine and other endodermal lineages. This insight led to development of a planar β cell 
differentiation protocol. Other protocols use suspension (Pagliuca F W  Gurtler M, Segel M, Van 
Dervort A, Ryu J H, Peterson Q P, Greiner D and Melton D A 2014; Rosado-Olivieri et al. 2019; 
Russ et al. 2015; Velazco-Cruz et al. 2019b; Veres et al. 2019) or pseudo-suspension air-liquid 




technical expertise required for SC-β cell differentiations. Using a novel planar differentiation 
protocol with actin depolymerizer latrunculin A driving endocrine specification, through NGN3 
upregulation, the authors generate SC-β cells which undergo dynamic GSIS. When these SC-β 
cells are transplanted into mice, they rapidly reversed severe preexisting diabetes at a rate 
resembling that achieved by cadaveric islets. 
In a controlled and parallel fashion, Hogrebe et al. compared his planar differentiated β cells to 
suspension differentiated β cells using the Velazco-Cruz et al. protocol. Using the HUES8 cell 
line, for which the two protocols were optimized, the suspension protocols had higher percent 
yields of CP+ NKX6.1+ SC-β cells. Functionally, planar and suspension derived SC-β cells were 
similar when assayed by static and dynamic GSIS as well as insulin content. When assayed by 
real-time PCR, the planar and suspension derived SC-β cells were similar. An equal number of 
planar and suspension derived SC-β cells were transplanted into diabetic mice. Diabetes reversal 
with planar differentiated β cells occurred in two weeks, while the suspension protocol took 5 
weeks. This discrepancy in diabetes cure speed is interesting, as in vitro functional and 
transcriptomic assays did not show evident differences between the two protocols and based on 
reported differentiation efficiencies the suspension protocol generates a higher proportion of SC-
β cells. Single-cell RNA sequencing, comparing transcriptomes of planar and suspension derived 
SC-β cells could reveal further insights into the source of this discrepancy. Importantly, the 
Hogrebe et al. planar protocol was able to successfully differentiate SC-β cells from multiple 
pluripotent stem cell lines, with some cell lines matching cadaveric islets in function when 
assayed with dynamic perfusion assays. While the HUES8 suspension and planar derived SC-β 




to different cell lines. The robustness of the planar Hogrebe et al. differentiation protocol 
facilitates studies using more than one cell line (Maxwell et al. 2020a; Velazco-Cruz et al. 2020). 
Using a sorting approach for CD177/NB1 glycoprotein, Mahaddalkar et al. isolated anterior 
definitive endoderm cells with increased pancreatic and β cell potential (Mahaddalkar et al. 
2020). The authors characterize CD177+ cells to have increase PDX1 and NKX6.1 pancreatic 
progenitor potential when compared to unsorted and CD275+ definitive endoderm populations. 
Additionally, this work shows canonical WNT inhibition by IWP2 treatment to increase 
pancreatic progenitor differentiation efficiency, a finding supported by previous publications 
(Davenport et al. 2016; Loh et al. 2014; Zhu et al. 2016). Differentiation of CD177+ cells toward 
β cells resulted in improved differentiation efficiency and function relative to unsorted cells. 
CD177+ cells presented a first phase insulin response with no second phase, while unsorted cells 
did not present a first or second phase insulin secretion (Mahaddalkar et al. 2020). The cells were 
not transplanted into mice. 
Direct comparison of these studies is difficult, as assays evaluating function are variable, 
including technical methodologies, normalization strategies, and in vivo models differ. 
Normalizing SC-β cells to cadaveric human islet insulin secretion is imperfect, as cadaveric islet 
function is highly variable within and between studies (Nair et al. 2019; Pagliuca et al. 2014; 
Velazco-Cruz et al. 2019b; Veres et al. 2019). Standardized static and dynamic GSIS assays, 
normalized to DNA, can greatly facilitate comparison of differentiation protocols while imposing 
minimal burden on investigators. Standardization of in vivo assays are more challenging, as 
many mouse and diabetic models exist with variable severity of diabetes. By providing 
standardized in vitro GSIS results, individual researchers can better compare protocols and guide 




1.5 Forging a Path Forward 
 
Despite advances, current SC-β cells lack the functional maturity of cadaveric islets. In the 
continuing quest to functionally mature SC-β cells, teams are employing novel technologies and 
approaches, such as single-cell sequencing, genetic engineering, cell sorting, and drug screening, 
to identify factors which contribute to β cell differentiation and function. Recent publications 
have compared gene expression between adult and fetal or juvenile islets, with many adult genes 
having potential roles in the functional maturation of SC-β cells. ERRγ has been characterized to 
be enriched in adult vs neonatal mouse β cells and mice deficient of β cell ERRγ fail to properly 
regulate their blood glucose (Yoshihara et al. 2016). Yoshira et al. differentiates hPSCs toward 
an immature β-like state in which many β cells genes are expressed but are incapable of 
undergoing in vitro GSIS. The authors overexpress ERRγ in these β-like cells and observed 
improvements to mitochondrial respiration and the β-like cells gain the ability to undergo in 
vitro GSIS. Upregulation of ERRγ can potentially be used to further mature SC-β cells. 
However, since its effects were only observed in immature insulin-expressing endocrine cells 
incapable of undergoing in vitro GSIS with immature mitochondrial respiration, it may not 
translate to more advanced protocols which are more metabolically mature (Nair et al. 2019). In 
a separate study, Arda et al. shows islet function increases in adult vs juvenile human islets 
identifying several genes associated with age in β cells including ONECUT2, MAFA, TSHZ3, 
SIX2, and SIX3 (Arda et al. 2016). It remains to be investigated whether upregulation of these 
genes in SC-β cells can drive their functional maturation. 
Inhibition of YAP signaling has been shown to drive endocrine induction through neurogenin 




induction, using verteporfin, β differentiation efficiency and function is enhanced (Rosado-
Olivieri et al. 2019). Dynamic function is not assayed in this work. This work is supported by a 
previous study showing pancreatic progenitor endocrinogenesis is stimulated by YAP inhibition 
(Mamidi et al. 2018). Incorporation of YAP inhibitors during endocrine specification and YAP 
agonist during β cell maturation may drive improvements to β cell generation. 
Recent work (Ameri et al. 2017; Cogger et al. 2017; Mahaddalkar et al. 2020; Nair et al. 2019; 
Veres et al. 2019) has shown that enrichment of certain cell populations can ultimately improve β 
cell differentiation efficiency and function. Transcriptomic (Ameri et al. 2017) and proteomic 
(Cogger et al. 2017) approaches have revealed glycoprotein two as a cell surface marker 
beneficial for sorting PDX1+/NKX6.1+ pancreatic progenitors improving β cell differentiation 
efficiency. Although functional improvements were not seen, this strategy may increase the 
proportion of β cells generated using enhanced differentiation protocols. Enrichment of the β cell 
population through sorting may enhance the functional maturation of SC-β cells (Nair et al. 
2019; Veres et al. 2019). Whether this improvement is through cell-cell contact, paracrine 
signaling, or the removal of inhibitory cell types, such as enterochromaffin cells (Veres et al. 
2019), remains to be determined with more robust studies necessary. Cell enrichment using cell 
sorting limits large scale production of SC-β cells. However, the scale of production necessary 
for SC-β cells may be compatible with magnetic-activated cell sorting approaches, particularly as 
they have proven beneficial. Additionally, identification of markers such as glycoprotein two can 
guide the search for small molecules to increase the population of cells expressing the desired 




successful, with the identification of Rho-kinase inhibitor H1152, capable of increasing MAFA 
and UCN3 expression (Ghazizadeh et al. 2017). 
Single-cell sequencing technologies are rapidly advancing our understanding of β cell fate, 
differentiation, and functional maturation. Several studies have increasingly elucidated the β cell 
transcriptome (Baron et al. 2016a; Segerstolpe et al. 2016a; Veres et al. 2019; Y. J. Wang et al. 
2016; Xin et al. 2016), revealing novel β cell enriched genes which may be used as markers for 
driving β cell functional maturation. Recently, single-cell patch-clamp sequencing was used 
linking β cell gene expression to functional phenotypes revealing sets of genes correlating with β 
cell function (Camunas-Soler et al. 2020; Veres et al. 2019) performed single-cell sequencing at 
multiple stages during SC-β cell differentiations revealing transcriptomic profiles of each stage 
and genes whose expression is correlated to the acquisition of function by SC-β cells. Epigenome 
analysis of SC-β cell differentiation reveal LMX1B as a regulator of endocrine specification and 
circadian rhythms as a component toward SC-β cell functional maturation (Alvarez-Dominguez 
et al. 2020). These studies give researchers a more accurate β cell transcriptomic model to guide 
differentiation protocol development. To further advance SC-β cell technology, researchers must 
continue efforts to build our understanding of β cell development which guides development of β 
cell differentiation protocols. 
1.6 Discussion 
 
SC-β cells are a promising cell source for diabetes cell therapy, disease modeling, and 
understanding human development. The use of small molecules and growth factors to drive stem 




amenable to scale-up and genetic perturbations. Since the first fully in vitro differentiation 
protocols (Pagliuca et al. 2014; Rezania et al. 2014) capable of generating glucose responsive β 
cells, the field has significantly advanced. Through the optimization of differentiation protocols, 
including the removal of ALK5i during the final stage of differentiation and reaggregation driven 
endocrine enrichment, enhanced SC-β cells have greater glucose responsiveness undergoing 
dynamic GSIS. Currently, SC-β cells are still less functional than cadaveric islets secreting lower 
amounts of insulin and a stable but lower in magnitude second phase insulin secretion (Nair et al. 
2019; Velazco-Cruz et al. 2019b; Veres et al. 2019). Transcriptionally, SC-β cells resemble 
cadaveric islets more so than fetal islets, however critical differences remain, such as reduced 
expression of maturation factors MAFA and SIX3 (Veres et al. 2019). Using recently published 
technologies and approaches our understanding of β cell development is improving, guiding the 
development of novel protocols capable of generating SC-β cells with function matching that of 
primary islets. Generation of fully functionally mature SC-β cells may be possible in the next 
few years and will drive diabetes cell therapies forward while providing a robust model for 
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Recent advances in human pluripotent stem cell (hPSC) differentiation protocols have generated 
insulin-producing cells resembling pancreatic β cells. While these stem cell-derived β (SC-β) 
cells are capable of undergoing glucose-stimulated insulin secretion (GSIS), insulin secretion per 
cell remains low compared with islets and cells lack dynamic insulin release. Herein, we report a 
differentiation strategy focused on modulating transforming growth factor β (TGF-β) signaling, 
controlling cellular cluster size, and using an enriched serum-free media to generate SC-β cells 
that express β cell markers and undergo GSIS with first- and second-phase dynamic insulin 
secretion. Transplantation of these cells into mice greatly improves glucose tolerance. These 
results reveal that specific time frames for inhibiting and permitting TGF-β signaling are 
required during SC-β cell differentiation to achieve dynamic function. The capacity of these cells 




Diabetes mellitus is a global health problem affecting over 400 million people worldwide and is 




principally caused by the death or dysfunction of insulin-producing β cells found within the islets 
of Langerhans in the pancreas, resulting in improper insulin secretion and failure of patients to 
maintain normal glycemia, which in severe cases can cause ketoacidosis and death. Patients are 
often reliant on insulin injections but can still suffer from long-term complications, including 
retinopathy, neuropathy, nephropathy, and cardiovascular disease (Nathan DM, Genuth S, 
Lachin J 1993). An alternative treatment is replacement of the endogenous β cells by 
transplantation of pancreatic islets (Bellin et al. 2012; Hering et al. 2016; Lacy and Kostianovsky 
1967; Scharp et al. 1990; Shapiro et al. 2000). While this therapy has had clinical success, 
limited availability of cadaveric donor islets largely hampers its widespread application (Bonner-
Weir and Weir 2005). 
Differentiation of human pluripotent stem cells (hPSCs) into stem cell-derived β cells (SC-β 
cells) is a promising alternative cell source for diabetes cell replacement therapy as well as other 
applications, such as modeling disease and studying pancreatic development (Millman and 
Pagliuca 2017a). Through modulation of pathways identified from embryonic development, 
studies with hPSCs have detailed protocols for generating cells that resemble 
early endoderm and pancreatic progenitors (Amour et al. 2006; K A D’Amour et al. 2005; Evert 
Kroon et al. 2008; Nostro et al. 2015; Rezania et al. 2012), the latter of which can be transplanted 
into rodents and spontaneously differentiated into β-like cells after several months (Bruin et al. 
2015; Evert Kroon et al. 2008; Millman et al. 2016; Rezania et al. 2012). 
We (Pagliuca et al. 2014) and others (Rezania et al. 2014) published similar approaches for 
generating SC-β cells in vitro that in part use the compound Alk5 inhibitor type II (Alk5i) to 
inhibit transforming growth factor β (TGF-β) signaling during the last stages of differentiation. 




secretion (GSIS) in static incubations, expressing β cell markers, and controling blood sugar in 
diabetic mice after several weeks. However, even with this significant breakthrough, these cells 
had inferior function compared with human islets, including lower insulin secretion and little to 
no first- and second-phase insulin release in response to a high glucose challenge, demonstrating 
that these SC-β cells were less mature than β cells from islets. Several follow-up studies have 
been performed introducing additional differentiation factors or optimizing the process but have 
failed to bring SC-β cell function equivalent to human islets (Ghazizadeh et al. 2017; Millman et 
al. 2016; Russ et al. 2015; Zhu et al. 2016). 
Here we report a six-stage differentiation strategy that generates almost pure populations 
of endocrine cells containing β-like cells that secrete high levels of insulin and express β cell 
markers. This is achieved by modulating Alk5i exposure to inhibit and permit TGF-β signaling 
during key stages in combination with cellular cluster resizing and enriched serum-free media 
(ESFM) culture. These cells are glucose responsive, exhibiting first- and second-phase insulin 
release, and respond to multiple secretagogues. Transplanted cells greatly improve glucose 
tolerance in mice. We identify that inhibiting TGF-β signaling during stage 6 greatly reduces the 
function of these differentiated cells while treatment with Alk5i during stage 5 is necessary for a 
robust β-like cell phenotype. 
2.3 Results 
2.3.1 Differentiation to Glucose-Responsive SC-β Cells In Vitro 
 
We set out to develop an improved differentiation protocol starting from the approach we 
described in Pagliuca et al. (2014) using the HUES8 cell line. We included Y27632 during stages 
3 to 4 and activin A during stage 4 as we reported previously (Millman et al. 2016) to help 




(Nostro et al. 2015). We also developed an ESFM for stage 6 to replace the serum-containing 
media used previously to have a serum-free protocol. During our protocol pilot studies, we 
observed that both resizing clusters and removal of Alk5i and T3 increased insulin 
secretion while maintaining the C-peptide+ population (Figures S2.1A and S2.1B). 
Combining these modifications resulted in our six-stage differentiation protocol outlined 
in Figure 2.1A. Stage 6 cells are grown as clusters in suspension culture (Figure 2.1B) that 
averaged 172 ± 34 μm (mean ± SD; n = 353 individual clusters) in diameter, less than half the 
diameter of the clusters before resizing, which was 364 ± 55 μm (n = 155 individual clusters). 
Stage 6 clusters stained red for the zinc-chelating dye dithizone, which stains β 
cells. Immunostaining of sectioned clusters revealed most cells to be C-peptide+, a protein also 
produced by the INS gene, in addition to PDX1+ and NKX6-1+, β cell markers (Figure 2.1C). A 
subset of cells stained positive for GCG or were polyhormonal, staining positive for both C-
peptide and GCG. These polyhormonal cells are known to not to resemble adult β cells and are 
not functional (Kevin A D’Amour et al. 2006; Hrvatin et al. 2014). 
We tested function of stage 6 cells generated with our differentiation protocol using both static 
(Figures 2.1D, 1E, and S2.1C) and dynamic GSIS assays (Figures 2.1F and S2.1D) and found 
that not only do the cells secrete insulin but also increase insulin release when moved from low 
to high glucose. With static GSIS, while there was some variability, stage 6 cells increased 
insulin secretion on average by a factor of 3.0 ± 0.1 when moved from 2 to 20 mM glucose. This 
is an improvement compared with cells generated with the protocol described in Pagliuca et al. 
(2014) (1.4 ± 0.1), referred to here as the Pagliuca protocol, but less than human islets (3.2 ± 0.1) 




response to 5.6 mM glucose but did increase secretion in response to higher concentrations (11.1 
and 20 mM), indicating that the cells are only stimulated at higher glucose threshold 
(Figure 2.1E). In terms of insulin secretion per cell, stage 6 cells secreted on average 5.3 ± 
0.5 μIU/103 cells at 20 mM glucose, 9.2 ± 1.1 times more than cells generated with the Pagliuca 
protocol and 2.3 ± 0.3 times less than human islets, on average (Figure 2.1D). It is important to 
note that our insulin values with the Pagliuca protocol are within range of the 2014 report but 
were lower on average, with differentiated HUES8 reported to secrete 0.2–2.6 μIU/103 cells 
(average 1.4) and increase secretion by 0.4–4.1 (average 1.7) to high glucose. 
With dynamic GSIS, stage 6 cells displayed a rapid first-phase insulin release within 3–5 min of 
high glucose exposure, increasing insulin secretion by a factor of 7.6 ± 1.3 to 159 ± 21 μIU/μg 
DNA, higher than stage 6 cells generated from the Pagliuca protocol (1.7 ± 0.2× increase to 11 ± 
1 μIU/μg DNA) but lower than human islets (15.0 ± 2.4× increase to 245 ± 26 μIU/μg DNA) 
(Figure 2.1F). Second-phase insulin secretion was observed with continued high glucose 
exposure, with cells maintaining 2.1 ± 0.3 higher insulin secretion than the initial low glucose, a 
higher increase than with the Pagliuca protocol (0.9 ± 0.1) but lower than human islets (6.7 ± 
0.8) (Figure 2.1F). When the cells were returned to low glucose, insulin secretion from stage 6 
cells returned to a reduced rate. Elevating insulin secretion and displaying first- and second-
phase insulin release to a high glucose challenge are key features of β cell behavior. Overall, 
stage 6 cells generated with this differentiation strategy produces cells with clear first- and 
second-phase insulin secretion, which was not demonstrated by Pagliuca et al. 
(2014) and Rezania et al. (2014) and not seen with stage 6 cells produced with the Pagliuca 




have lower insulin secretion per cell at high glucose, lower glucose stimulation on average, and 
slightly slower first-phase insulin release. 
To further characterize stage 6 cells generated with our differentiation protocol, we 
immunostained cells with a panel of pancreatic islet markers (Figures 2.2A–2C and S2.2). The 
vast majority of cells expressed CHGA (96% ± 1%), a pan-endocrine marker, and most cells 
expressed C-peptide (73% ± 3%) (Figure 2.2). These fractions are higher than in stage 6 cells 
generated with the Pagliuca protocol (Figure S2.2) and reported in Pagliuca et al. (2014). Many 
C-peptide+ cells from both protocols expressed other markers found in β cells and expression of 
the other pancreatic hormones was observed (Figures 2.2 and S2.2). The majority of C-peptide+ 
cells expressed NKX6-1 (Figure 2.2) and were monohormonal, which we presumed to be the 
SC-β cell population as done previously (Pagliuca et al. 2014). The fraction of C-peptide+ cells 
not expressing another hormone was increased compared with stage 6 cells generated with the 
Pagliuca protocol and reported in (Pagliuca et al. 2014), while the fraction of these cells 
expressing another hormone was comparable (Figures 2.2 and S2.2). These data show that stage 
6 cells generated with our differentiation strategy are predominantly pancreatic endocrine with 
the majority expressing C-peptide. 
We measured expression of several genes compared with stage 6 cells generated with the 
Pagliuca protocol and human islets (Figures 2.2D and S2.3). Many islet and β cell genes were 
increased compared with the Pagliuca protocol, including INS, CHGA, NKX2-2, PDX1, NKX6-
1, MAFB, GCK, and GLUT1. Interestingly, LDHA and SLC16A1, disallowed β cell genes, had 
reduced expression in our stage 6 cells compared with both the Pagliuca protocol and human 




of CHGA, NKX6-1, MAFB, GCK, and GLUT1 compared with human islets. However, INS, 
GCG, SST, and particularly MAFA and UCN3 had reduced expression compared with stage 6 
cells. However, several recent reports have provided evidence that question the utility of MAFA 
and UCN3 in evaluating human SC-β cell maturation. MAFA expression is low in juvenile 
human β cells (Arda et al. 2016). MAFB is expressed in human but not mouse β cells (Arda et al. 
2016; Tritschler et al. 2017; Xin et al. 2016). UCN3 expression is much higher in mouse than 
human β cells (Xin et al. 2016) and is also expressed by human α cells (Baron et al. 2016a; 
Tritschler et al. 2017). These data show that our stage 6 cells have improved gene expression for 
many markers compared with the Pagliuca protocol and, while the expression of several β cell 
markers are equal to or great than human islets, other markers remain low. 
2.3.2 Transplantation of SC-β Cells into Glucose-Intolerant Mice 
To evaluate the functional potential of stage 6 cells in vivo, we first transplanted cells under the 
renal capsule of non-diabetic mice and evaluated the ability of the graft to respond to a glucose 
challenge (Figure 2.3A). We observed that, even after extended time post-transplantation 
(6 months), the grafts responded to a glucose injection by increasing human insulin by a factor of 
1.9 ± 0.5. Excision and immunostaining of the transplanted kidneys revealed C-peptide+ cells 
that tended to be clustered together in addition to other pancreatic endocrine and exocrine 
markers (Figures 2.3B and S2.4A). To more rigorously evaluate stage 6 cells in vivo, we 
transplanted a separate mouse cohort that had been chemically induced to be diabetic 
with streptozotocin (STZ) and evaluated function at early (10 and 16 day) and late (10 week) 
time points. After only 10 days post-transplantation, STZ-treated mice receiving stage 6 cells had 
greatly improved glucose tolerance compared with STZ-treated sham mice and had similar 




insulin 16 days after transplantation revealed high insulin concentrations that increased by a 
factor of 2.3 ± 0.6 with a glucose injection to 16.6 ± 3.1 μIU/mL (Figure 2.3E). These values are 
greater than what was reported in Pagliuca et al. (2014) under similar conditions, which had an 
insulin increase of 1.4 ± 0.3 and concentration of 3.8 ± 0.8 μIU/mL. Observing our cohort 
10 weeks after transplantation revealed similar results as the 10- and 16-day data, with 
transplanted mice having greatly improved glucose tolerance (Figures 2.3F and 2.3G) and 
glucose-responsive insulin secretion (Figure 2.3H). Mice not receiving STZ had similar glucose 
tolerance as mice receiving a therapeutic dose of human islets (Pagliuca et al. 2014). Mice that 
did not receive stage 6 cells had undetectable human insulin and mice that received STZ had 
drastically reduced mouse C-peptide compared with non-STZ-treated mice (Figures S2.4B and 
S4C). Grafts from these STZ-treated mice contained cells that expressed β cell markers in 
addition to other endocrine and exocrine markers (Figure S2.4D). Overall these data demonstrate 
that stage 6 cells generated with our protocol are functional both at early and late time 
points in vivo, greatly improving glucose tolerance to equal that of non-STZ-treated mice. 
2.3.3 Characterization of SC-β Cell Dynamic Function 
 
Since the differentiation protocol produces cells that are capable of dynamic insulin secretion, we 
studied this phenotype in more detail. We performed dynamic GSIS on cells as they progressed 
through stage 6 (Figure 2.4A). We observed that robust dynamic function was transient, with 
cells at 5 days secreting low amounts of insulin and exhibiting weak first- and second-phase 
response, with later time points (9–26 days) secreting higher amounts of insulin with a clear first- 
and second-phase response. During this time, the fraction of C-peptide+ cells decreased slightly 
(Figure S2.5A). By 35 days, insulin secretion at low glucose had risen such that first and second 




to acquire dynamic function, this function persists for weeks, but after extended in vitro culture 
glucose responsiveness is lost. Similarly, cadaveric human islets are known to have a limited 
functional lifetime in vitro, but the cause of this is not clear. These data further suggest an 
optimal time frame for these cells to be used in transplantation and drug-screening studies. 
To further characterize dynamic insulin secretion, we performed perifusion experiments to assay 
whether SC-β cells could respond to sequential challenges with several known secretagogues 
(Figure 2.4B). After an initial high glucose challenge, SC-β cells were able to respond to a 
second high glucose-only challenge, albeit less strongly than the first challenge, and extending 
the first glucose challenge to 1 hr in a separate experiment did not reduce insulin secretion 
(Figure 2.4C). Addition of other secretagogues during the second challenge further increased 
insulin secretion (Figure 2.4B). Membrane depolarizers KCl and L-arginine had the largest 
increases. Tolbutamide (blocks potassium channel), 3-isobutyl-1-methylxanthine (IBMX) (raises 
cytosolic cAMP), and exendin-4 (agonist of GLP-1 receptor) also increased insulin secretion 
over high glucose alone. Not only was insulin secretion increased but it rose faster than with high 
glucose alone. However, we noted that the response of stage 6 cells to KCl challenge was 
stronger than in human islets (Figure S2.5B), an observation made by others comparing β-like 
cells to human islets (Rezania et al. 2014), possibly indicative of continued immature or juvenile 
β cell phenotype. Taken together, these data show that SC-β cells can respond to several 
secretagogues that have diverse modes of action and have potential application in drug screening. 
2.3.4 Role of TGF-β Signaling in SC-β Cell Differentiation and Maturation 
 
After having evaluated SC-β cells generated with our protocol, we investigated the protocol 
changes that were made to gain insights into SC-β cell differentiation and maturation. We found 




significant GSIS in a static assay, similar to data from the Pagliuca protocol (Figure 2.1D), 
omission of Alk5i drastically increased insulin secretion and glucose stimulation (Figures 2.5A 
and S2.6A). Insulin content also increased with removal of Alk5i during stage 6 (Figure 2.5B), 
but the proinsulin/insulin ratio remained similar (Figure 2.5C), suggesting that the increased 
insulin content is not due to hormone processing. Furthermore, the fraction of cells expressing 
pancreatic endocrine markers, including C-peptide, remained similar between DMSO- and 
Alk5i-treated cells (Figures 2.5D, 2.5E, and S2.6B). Gene expression was similar overall with 
and without Alk5i treatment, with cluster resizing typically having a larger effect (Figure S2.6C). 
Cells treated with Alk5i during stage 6 also had dramatically reduced insulin secretion with the 
dynamic GSIS assay, displaying weak to no first- and second-phase response (Figure 2.5F), 
similar to cells generated with the Pagliuca protocol (Figure 2.1F). These data show that Alk5i 
treatment during stage 6 inhibits functional maturation of SC-β cells. 
Our studies with Alk5i during stage 6 suggested that permitting TGF-β signaling was necessary 
for robust functional maturation of SC-β cells, as inhibition of TGFBR1 is the canonical function 
of Alk5i. To test this hypothesis, we first used western blot analysis to validate that TGF-β 
signaling was occurring in our stage 6 cells via SMAD phosphorylation (Figure 2.6A). Alk5i 
treatment diminished phosphorylated SMAD, confirming that TGF-β signaling was indeed 
occurring and inhibited by Alk5i. SMAD phosphorylation was observed in stage 6 clusters 
regardless of whether they were resized, consistent with observations that Alk5i treatment 
reduced GSIS regardless of resizing (Figure S2.7). Next, we generated two lentiviruses carrying 
short hairpin RNA (shRNA) designed to knock down TGFBR1 (TGFBR1 no. 1 and no. 2). 
These viruses were capable of reducing TGFBR1 transcript compared with control virus 




and S2.7C), albeit to much lesser extent than Alk5i treatment (Figure 2.6A). Similar to Alk5i 
treatment (Figures 2.5A and 2.5F), stage 6 cells transduced with shRNA against TGFBR1 had 
reduced insulin secretion and reduced positive glucose responsiveness in the static GSIS assay 
(Figure 2.6C) and blunted glucose response in the dynamic GSIS assay (Figure 2.6D). These 
data show that permitting TGF-β signaling during stage 6 is important for SC-β cell functional 
maturation, which is inhibited by treatment with Alk5i. 
Finally, we studied the role of Alk5i during stage 5 of differentiation to evaluate its effects on 
differentiation toward pancreatic endocrine cells, as it had been used previously for endocrine 
induction (Millman et al. 2016; Pagliuca et al. 2014; Rezania et al. 2014; Russ et al. 2015; Zhu et 
al. 2016). These experiments were performed as outlined in Figure 2.1A in the presence or 
absence of Alk5i. We observed that the fraction of cells differentiated to endocrine cells 
(CHGA+) was unchanged but the fraction of cells differentiated to a C-peptide+ phenotype was 
decreased by omitting Alk5i (Figures 2.7A–2.7C). Similarly, the fraction of cells co-expressing 
C-peptide and NKX6-1, an important transcription factor for specifying β cells (Rezania et al. 
2013; Rieck, Bankaitis, and Wright 2012), was decreased by omitting Alk5i. INS and GCG gene 
expression decreased with Alk5i omission, but surprisingly SST expression was slightly 
increased (Figure 2.7D). Expression of NKX6-1 and PDX1 were reduced without Alk5i 
(Figure 2.7E), while expression of several pancreatic endocrine markers were either unchanged 
or only slightly changed (Figure 2.7F). To further test the importance of Alk5i during stage 5, 
cells treated with or without Alk5i during stage 5 were further cultured for 7 days in stage 6 
without Alk5i nor cluster resizing, and insulin secretion was substantially higher in cells treated 
with Alk5i during stage 5 (Figure 2.7G). Taken together, these data show that Alk5i treatment 




endocrine cells, and is necessary for high insulin secretion of resulting SC-β cells. In addition, 
these observations illustrate the importance of stage-specific treatment of the TGF-β signaling-
inhibitor Alk5i to both generate and functionally mature SC-β cells. 
2.4 Discussion 
 
Here we demonstrate that enhanced functional maturation of SC-β cells is achieved with our six-
stage differentiation strategy. These cells secrete a large amount of insulin and are glucose 
responsive, displaying both first- and second-phase insulin release. This differentiation procedure 
generates almost pure endocrine cell populations without selection or sorting, and most cells 
express C-peptide and other β cell markers. Upon transplantation into STZ-treated mice, glucose 
tolerance is rapidly restored and function persists for months. These SC-β cells respond to 
multiple secretagogues in a perifusion assay. We found modulating TGF-β signaling to be crucial 
for success, with inhibition during stage 5 increasing SC-β cell differentiation but inhibition 
during stage 6 reducing function and insulin content. Permitting TGF-β signaling during stage 6 
was necessary for robust dynamic function. 
Even though the protocols reported previously by us (Pagliuca et al. 2014) and others (Rezania et 
al. 2014) both generated β-like cells with much greater function and better marker expression 
than prior reports (Hrvatin et al. 2014), robust first- and second-phase insulin release in response 
to glucose stimulation was not observed. Both protocols inhibited TGF-β signaling during the 
final stage of differentiation, and many subsequent reports also include inhibitors of TGF-β 
signaling without demonstrating proper dynamic function (Ghazizadeh et al. 2017; Millman et al. 
2016; Song and Millman 2017; Sui et al. 2018; Vegas et al. 2016; Zeng et al. 2016; Zhu et al. 
2016). However, a major observation of the current study is that correct modulation of TGF-β 




to functional SC-β cells, with permitting TGF-β signaling being required for improved functional 
maturation during stage 6. 
SC-β cells in this report were able to control glucose in STZ-treated mice rapidly within 10 days. 
Prior reports with in-vitro-differentiated β-like cells without demonstrated robust dynamic 
function have successfully controlled blood sugar with a glucose tolerance test or demonstrated 
glucose-responsive serum human insulin/C-peptide in mice after several weeks or months 
(Millman et al. 2016; Pagliuca et al. 2014; Rezania et al. 2014; Vegas et al. 2016; Zhu et al. 
2016), but our SC-β cells had higher measured human insulin levels compared with Pagliuca 
et al. (2014) with equal cell numbers transplanted. Vegas et al. (2016) did demonstrate reduced 
blood glucose within a week but did not test glucose tolerance or measure human insulin until 
much later. Currently, a key limitation in diabetes cell replacement therapy is the need for 
sustainable source of functional β cells (Weir, Cavelti-Weder, and Bonner-Weir 2011), and 
improving the quality of SC-β cells to be transplanted helps overcome this challenge (Tomei, 
Villa, and Ricordi 2015). Transplantation of immature pancreatic progenitor cells are an 
alternative cell type that has shown promise in rodents, where some cells 
undergo in vivo maturation to β-like cells after several months (Bruin et al. 2015; E Kroon et al. 
2008; Millman et al. 2016; Rezania et al. 2012). However, the mechanism is unknown, and how 
successful the process would be in humans is not clear, especially since the efficiency between 
rats and mice is very different (Bruin et al. 2015). Our process for making SC-β cells is scalable, 
with the cells grown and differentiated as clusters in suspension culture. The use of clusters in 
suspension culture allows flexibility for many applications, such as large animal transplantation 




patient cells and disease pathology (<108 cells) (Kudva et al. 2012; Maehr et al. 2009; Millman et 
al. 2016; Shang et al. 2014; Simsek et al. 2016; Teo et al. 2013). 
Our strategy enhances the utility of in-vitro-differentiated SC-β cells for drug screening due to 
their improved kinetics. Proper dynamic insulin release is an important feature of β cell 
metabolism that is commonly lost in diabetes (Caumo and Luzi 2004; Del Prato and Tiengo 
2001; Seino, Shibasaki, and Minami 2011; Zhang et al. 2001). We have established a renewable 
resource of SC-β cells with dynamic insulin release that can be used to better study the 
mechanism of β cell failure in diabetes and demonstrated their response to several secretagogues. 
The culmination of numerous modifications to the protocol produced SC-β cells exhibiting 
dynamic glucose response. In addition to modulating TGF-β signaling, other notable changes 
included the removal of serum, reducing cluster size, and the lack of several additional factors 
(T3, N-acetyl cysteine, Trolox, H1152, and R428) used in other reports during the last stage. We 
hope that these insights provide the basis for further innovations for differentiating SC-β cells 
and improving function, especially as a recent report indicates there may be multiple pathways to 
β cells (Petersen et al. 2017). While we demonstrate reproducibility of the protocol across 
multiple cell lines, marker expression and function were greatest in the HUES8 cell line. As this 
protocol was initially developed for this line, we suspect additional optimization to be beneficial 
when applying this protocol to additional lines. 
Even with these functional improvements over previously published SC-β cells, islets averaged 
higher insulin secretion and glucose stimulation, particularly second-phase release. These 
differences are more pronounced when comparing the best human islets in this dataset, which 
secreted 21 μIU/103 cells and had stimulated insulin increase of 11, to the best stage 6 cells, 




cells had reduced average insulin secretion at low glucose in static assays, but elevated insulin 
secretion at low glucose in perifusion assays compared with islets on average, perhaps due to 
paracrine differences. Comparisons with islets were complicated due to donor-to-donor variation, 
which has been observed previously (Kayton et al. 2015; Lyon et al. 2016; Pagliuca et al. 2014). 
We do note that islets in our study were typically more functional than in other studies 
(Ghazizadeh et al. 2017; Pagliuca et al. 2014; Rezania et al. 2014; Russ et al. 2015; Sui et al. 
2018), which we believe is important to rigorously benchmark SC-β cells. In addition, some islet 
genes remain underexpressed in our cells. Furthermore, while the data we generated with the 
Pagliuca protocol were within the range of data presented in the 2014 report, we acknowledge 
that the static GSIS values were lower on average, likely due in part to technical differences in 
how the assays were performed. Another potential contributor is batch-to-batch variability, as 
stated in the 2014 report, which could be caused by the use of different lots of serum during 
stage 6 and was eliminated in our protocol. Even with these difficulties and insights, we 
acknowledge that even further maturation of SC-β cells is possible, building on this report and 
the original 2014 breakthroughs. 
This study provides insights into the role of TGF-β signaling in functional maturation. Prior 
reports are unclear on this topic, with some showing TGF-β inhibition to benefit (Lin et al. 2009) 
and others to harm (Totsuka et al. 1989) secretion. Inhibition has been shown to promote 
replication (Dhawan et al. 2016), protect against stress-induced loss of phenotype (Blum et al. 
2014; Millman et al. 2016), and reduce apoptosis in a GLIS3 knockout model (Amin et al. 2018). 
Interestingly, we also observed that removal of Alk5i during stage 5 does not affect the overall 
percentage of cells expressing CHGA, but influences the expression of INS, GCG, and SST, 




that we did not identify the downstream effectors of TGF-β signaling responsible for the reported 
phenotypes, and further study is warranted. 
2.5 Experimental Procedures 
 
Culture of Undifferentiated Cells 
Undifferentiated hPSC lines were cultured using mTeSR1 in 30-mL spinner flasks on a rotator 
stir plate spinning at 60 rpm in a humidified 5% CO2 37°C incubator. Cells were passaged every 
3–4 days by single-cell dispersion. 
Cell Line Differentiation 
To initiate differentiation, undifferentiated cells were single-cell dispersed and seeded at 6 × 
105 cells/mL in a 30-mL spinner flask. Cells were cultured for 72 hr in mTeSR1 and then 
cultured in the differentiation media for 6 stages outlined in the supplemental experimental 
procedures found in published article, except where otherwise noted. Cells were resized the first 
day of stage 6 by incubating in Gentle Cell Dissociation Reagent and passing through a cell 
strainer. Assessment assays were performed between 10 and 16 days of stage 6 unless otherwise 
stated. 
Static GSIS 
Clusters were incubated at 2 mM glucose for a 1 hr equilibration in a transwell. The transwell 
was then drained and transferred into a new 2 mM glucose well, incubated 1 hr (first challenge), 
then transferred into a solution of 2, 5.6, 11.1, or 20 mM glucose (second challenge), incubated 
1 hr, and then normalized by cell count and insulin quantified with ELISA. 
Dynamic GSIS 
A perifusion system was assembled as reported previously (Bentsi-Barnes et al. 2011). Stage 6 




exposed to the indicated secretagogues, including glucose, Extendin-4, IBMX, tolbutamide, L-
arginine, and KCl. After sample collection, DNA and insulin were quantified. 
Transplantation Studies 
All animal work was performed in accordance to Washington University International Animal 
Care and Use Committee regulations. Mice were injected with ∼5 × 106 stage 6 cells under the 
kidney capsule (Pagliuca et al. 2014) and monitored up to 6 months by performing glucose 
tolerance tests and in vivo GSIS. 
Statistical Analysis 
Statistical significance was calculated using GraphPad Prism using the indicated statistical test. 
Slope and error in slope was calculated with the LINEST function in Excel. Data shown as mean 
± SEM unless otherwise noted or box-and-whiskers showing minimum to maximum point range, 







Figure 2.1. SC-β Cell Clusters undergo GSIS 
(A) Overview of our differentiation procedure. 
(B) Images of unstained whole stage 6 clusters under phase contrast (top) or stained 
with dithizone (DTZ) (bottom) imaged under bright field. Scale bars, 400 μm. 
(C) Immunostaining of sectioned stage 6 clusters stained for glucagon (GCG), NKX6-
1, PDX1, C-peptide (CP), or with the nuclei marker DAPI. Scale bar, 100 μm. 
(D) Human insulin secretion of stage 6 cells generated with the protocol from this study (n = 16), 




in a static GSIS assay. ∗∗p < 0.01, ∗∗∗∗p < 0.001 by one-sided paired t test. ###p < 0.001, ####p < 
0.0001 by one-way ANOVA Dunnett multiple comparison test compared with this study. 
(E) Static GSIS assay of stage 6 cells from this study subjected to either 2, 5.6, 11.1, or 20 mM 
glucose (n = 4). ∗p < 0.05, ∗∗∗p < 0.001, n.s., not significant by one-way ANOVA Dunnett 
multiple comparison test compared with 2 mM glucose. 
(F) Dynamic human insulin secretion of stage 6 cells generated with the protocol from this study 
(n = 12), stage 6 cells generated with the Pagliuca protocol (n = 4), and cadaveric human islets 
(n = 12) in a perfusion GSIS assay. Cells are perfused with low glucose (2 mM) except where 
high glucose (20 mM) is indicated. Act A, activin A; CHIR, CHIR9901; KGF, keratinocyte 
growth factor; RA, retinoic acid; Y, Y27632; LDN, LDN193189; PdbU, phorbol 12,13-
dibutyrate; T3, triiodothyronine; Alk5i, Alk5 inhibitor type II; ESFM, enriched serum-free 
medium. All stage 6 data shown are with HUES8. 









(A) Immunostaining of dispersed stage 6 clusters plated overnight and stained for chromogranin 
A (CHGA), GCG, somatostatin (SST), NEUROD1, NKX6-1, PDX1, PAX6, C-peptide (CP), or 
with DAPI. Scale bar, 100 μm. 
(B) Representative flow cytometric dot plots of dispersed stage 6 clusters immunostained for the 
indicated markers. 
(C) Box-and-whiskers plots quantifying fraction of cells expressing the indicated markers. Each 
point is an independent experiment. 
(D) Real-time PCR analysis of stage 6 cells generated with the protocol from this study (n = 8), 
stage 6 cells generated with the Pagliuca protocol (n = 5), and cadaveric human islets (n = 7). 
n.s., not significant, ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001 by one-way ANOVA 
Dunnett multiple comparison test compared with this study. All stage 6 data shown are with 
HUES8. 





Figure 2.3. SC-β Cells Greatly Improve Glucose Tolerance and Have Persistent Function 
for Months after Transplantation 
(A) Serum human insulin of a non-STZ-treated mouse cohort (n = 3) 6 months after 
transplantation fasted overnight 0 and 60 min after an injection of 2 g/kg glucose. ∗∗p < 0.01 by 




(B) Immunostaining of sectioned explanted kidneys of non-STZ-treated mice 6 months after 
transplantation for C-peptide, PDX1, or with DAPI. The white dashed line is manually drawn to 
show the border between kidney and graft (∗). Scale bars, 50 μm. 
(C) Glucose tolerance test (GTT) 10days after surgery for STZ-treated mice cohort without a 
transplant (STZ, No Txp; n = 6), untreated mice without a transplant (No STZ, No Txp; n = 5), 
and STZ-treated mice with a transplant (STZ, Txp; n = 6). ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 
0.001, ∗∗∗∗p < 0.0001 by two-way ANOVA Tukey multiple comparison. 
(D) Area under the curve (AUC) calculations for data shown in (C). ∗∗p < 0.01 by one-way 
ANOVA Tukey multiple comparison test. 
(E) Serum human insulin of STZ, Txp mice (n = 5) fasted overnight 0 and 60 min after an 
injection of 2 g/kg glucose. ∗∗p < 0.01 by one-sided paired t test. 
(F) GTT 10 weeks after surgery for STZ, No Txp mice (n = 6), No STZ, No Txp mice (n = 4), 
and STZ, Txp mice (n = 5). ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001 by two-way ANOVA Tukey 
multiple comparison test. 
(G) AUC calculations for data shown in (D). ∗∗∗p < 0.001 by one-way ANOVA Tukey multiple 
comparison test. 
(H) Serum human insulin of STZ, Txp mice (n = 5) fasted overnight 0 and 60 min after an 
injection of 2 g/kg glucose. ∗∗p < 0.01 by one-sided paired t test. All data shown are with 
HUES8. (A and B) are severe combined immunodeficiency (SCID)/Beige and (C–H) are non-
obese diabetic/SCID mice. 





Figure 2.4. SC-β Cells have Transient Dynamic Function In Vitro, Respond to Multiple 
Stimuli, and Sustain Second-Phase Insulin Secretion at High Glucose 
(A) Dynamic human insulin secretion cells in stage 6 for 5, 9, 15, 22, 26, and 35 days in a 
perfusion GSIS assay. Data for each individual time point is shown as mean ± SEM and the final 
graph shows only the means of each graph. Cells are perfused with low glucose (2 mM) except 




(B) Dynamic human insulin secretion of stage 6 cells in a perfusion GSIS assay treated with 
multiple secretagogues. Cells are perfused with low glucose (2 mM) except where high (20 mM) 
glucose is indicated (Glu), then perfused with a second challenge of high glucose alone or with 
additional compounds (tolbutamide, IBMX, and Extendin-4 on the left; KCL and L-arginine on 
the right) where indicated (Glu + Factor). Note that the high glucose-only challenge is shown in 
both left and right graphs and the scale change (n = 3 except glucose, which is n = 2). 
(C) Dynamic human insulin secretion of stage 6 cells in a perfusion GSIS assay with an extended 
high glucose treatment. Cells are perfused with low glucose (2 mM) except where high glucose 
(20 mM) is indicated (n = 3). All data shown are with HUES8. 





Figure 2.5. Alk5i Reduces SC-β Cell GSIS 
(A) Box-and-whiskers plot of human insulin secretion of stage 6 cells in static GSIS assay 
treated with DMSO or Alk5i (n = 9). ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001 by two-way paired t test; 
####p < 0.0001 by two-way unpaired t test. 
(B) Cellular insulin content of stage 6 cells treated with DMSO or Alk5i (n = 18). ∗∗∗∗p < 0.0001 




(C) Cellular proinsulin/insulin content ratio of stage 6 cells treated with DMSO or Alk5i (n = 
17). n.s., not significant by two-way unpaired t test. 
(D and E) Representative flow cytometric dot plots of dispersed stage 6 clusters immunostained 
for CHGA and PDX1 (D) or C-peptide and NKX6-1 (E). 
(F) Dynamic human insulin secretion of stage 6 cells treated with DMSO or Alk5i in a perfusion 
GSIS assay. Cells are perfused with low glucose (2 mM) except where high glucose (20 mM) is 
indicated (n = 12). All data shown are with HUES8. 
Data are shown as means ± SEM. 
 




(A) Western blot of stage 6 cells cultured with DMSO or Alk5i stained for 
phosphorylated SMAD 2/3 (pSMAD2/3), total SMAD 2/3 (tSMAD2/3), and actin. Data shown 
are from HUES8. 
(B) Real-time PCR of stage 6 cells transduced with lentiviruses containing GFP (control) or one 
of two sequences against TGFBR1 (TGFBR1 no. 1 and no. 2) (n = 3) shRNA. ∗∗∗∗p < 0.0001 by 
one-way ANOVA Dunnett multiple comparison test compared with GFP. 
(C) Western blot of stage 6 cells transduced with lentiviruses containing GFP or TGFBR1 no. 1 
shRNA. Data shown are from 1013-4FA. 
(D) Human insulin secretion of stage 6 cells in static GSIS assay transduced with lentiviruses 
containing GFP, TGFBR1 no. 1 or no. 2 shRNA (n = 3). ∗∗p < 0.01 by paired two-way t test. 
##p < 0.01 by one-way ANOVA Dunnett multiple comparison test compared with GFP. Data 
shown are from HUES8. 
(E) Dynamic human insulin secretion of stage 6 cells transduced with lentiviruses containing 
GFP or TGFBR1 no. 1 shRNA in a perfusion GSIS assay. Cells are perfused with low glucose 
(2 mM) except where high glucose (20 mM) is indicated (n = 4). Data shown are from HUES8. 






Figure 2.7. Alk5i Treatment during Stage 5 Is Important for Generation of Insulin-
Producing Cells 
(A and B) Representative flow cytometric dot plots of dispersed stage 5 clusters immunostained 
for CHGA and NKX6-1 (A) or C-peptide and NKX6-1 (B). 
(C) Fraction of cells expressing the indicated markers (n = 4 except CHGA, which was n = 




(D–F) Real-time PCR measuring relative gene expression of stage 5 cells cultured with DMSO 
or Alk5i for pancreatic hormones (D), β cell markers (E), or endocrine markers (F) (n = 6). ∗p < 
0.05, ∗∗p < 0.01, ∗∗∗∗p < 0.0001, or n.s., not significant by unpaired two-way t test. 
(G) Human insulin secretion at 20 mM glucose of cells cultured in stage 5 in either DMSO or 
Alk5i plus an additional 7days in stage 6 without Alk5i and without cluster resizing (n = 3). ∗∗p < 
0.01 by unpaired two-way t test. All data shown are from HUES8. 




2.7 Supplemental Figures 
 
Figure S2.1. Pilot data leading to our differentiation strategy and hiPSC reproduction, 




(A) Human insulin secretion of Stage 6 cells generated in CMRLS or ESFM, with or without 
resizing, and with or without factors (Alk5i and T3) in a static GSIS assay. The combinations 
investigated were (1) CMRLS, no resize, no factors (n=3), (2) CMRLS, yes resize, no factors 
(n=6), (3) ESFM, no resize, no factors (n=3), (4) ESFM, yes resize, no factors (n=3), (5) ESFM, 
yes resize, yes factors (n=3). HUES8 cell line used. (B) Flow cytometric dot plots of Stage 6 
cells generated in CMRLS or ESFM, with or without resizing, and with or without factors (Alk5i 
and T3) immunostained for C-peptide and NKX6-1. HUES8 cell line used. (C) Human insulin 
secretion in a static GSIS assay of three hiPSC lines (n=3 each). *P < 0.05, **P < 0.01, and ***P 
< 0.0001 by one-sided paired t-test. (D) Dynamic human insulin secretion of Stage 6 cells 
generated with two hiPSC lines in a perfusion GSIS assay. Cells are perfused with low glucose 






Figure S2.2. Additional immunostaining data for Stage 6 cells, related to Figure 2.2. 
(A) Immunostaining of Stage 6 clusters singlecell dispersed, plated overnight, and stained for the 
indicated markers. Stage 6 cells were generated from two hiPSC lines with the protocol from this 
paper and the HUES8 cell line with the Pagliuca protocol. Scale bar=50 μm for 1016SeVA and 




generated from two hiPSC lines with the protocol from this paper and the HUES8 cell line with 
the Pagliuca protocol stained with the indicated markers. 
 
 




Gene expression data for Stage 6 cells generated with our differentiation protocol from the 
HUES8 (n=8) and 1013-4FA (n=10) lines and human islets (n=7) measured with real-time PCR. 
The HUES8 and human islet plotted here is the same as from Figure 2. 
 
 
Figure S2.4. Additional immunostaining, serum human insulin measurements, and mouse 
C-peptide measurements, related to Figure 2.3.  
(A) Immunostaining of sectioned paraffin-embedded explanted kidneys of non-STZ-treated mice 




(GCG; α cell marker), somatostatin (SST; δ cell marker), KRT19 (ductal marker), and trypsin 
(acinar marker). Scale bar=25 µm. (B) Serum human insulin of STZ, No Txp mice (n=6) and No 
Stz, No Txp (n=5) fasted overnight 0 and 60 min after an injection of 2 g/kg glucose. (B) Serum 
mouse C-peptide of STZ, No Txp (n=6), No STZ, No Txp (n=4), and STZ, TXP (n=5). ****P < 
0.0001 and ns by one-way ANOVA Tukey multiple comparison test. (C) Immunostaining of 
sectioned paraffin-embedded explanted kidneys of STZ-treated mice 11 wk after transplantation 
for the indicated markers. Scale bar=25 µm. HUES8 cell line used. 
 
 
Figure S2.5. Temporal flow cytometry during Stage 6 and KCl challenge of human islets, 




(A) Flow cytometric dot plots of Stage 6 cells at early (9 d) and late (26 d) time points stained for 
C-peptide and NKX6-1. HUES8 cell line used. (B) Dynamic human insulin secretion of human 
islets in a perfusion GSIS assay perfused with low glucose (2 mM) except where high (20 mM) 
glucose is indicated (Glu), then perfused with a second challenge of high glucose with KCl 





Figure S2.6. Stage 6 cells generated from hiPSC undergo GSIS that is inhibited by Alk5i, 




(A) Human insulin secretion of Stage 6 cells generated from three hiPSC lines (1013-4FA, n=4; 
1016SeVA, n=3; 1019SeVF, n=3) in static GSIS assay treated with DMSO or Alk5i. *P < 0.05, 
**P < 0.01 , ****P < 0.0001 by twoway paired t-test; ##P < 0.01, ###P < 0.001, ####P < 0.0001 
by two-way unpaired t-test. The control data here is the same data in Figure S1. (B) Flow 
cytometry controls for Figure 5. The C-peptide/NKX6-1 control is the same as shown in Figure 
2. (C) Real-time PCR analysis of Stage 6 cells with or without resizing treated with Alk5i or 
DMSO (n=3). Data generated with the 1013-4FA cell line. 
 
 
Figure S2.7. Resized and unresized Stage 6 clusters have SMAD2/3 phosphorylation and 
reduced GSIS with Alk5i treatment and TGFBR1 #2 western blot, related to Figure 2.6.  
(A) Western blot of Stage 6 cells with and without resizing stained for phosphorylated SMAD 




Human insulin secretion of Stage 6 cells in static GSIS assay resized or unresized with treatment 
of DMSO or Alk5i. Data shown is from 1013-4FA. (C) Western blot of Stage 6 cells transduced 
with lentiviruses containing GFP or TGFBR1 #2 shRNA. Data shown is from HUES8. 
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Chapter 3:  
SIX2 Regulates Human β Cell Differentiation 
from Stem Cells and Functional Maturation 
In Vitro 
 
Partially adapted from Velazco-Cruz, Leonardo, Goedegebuure, Madeleine M., Maxwell, 
Kristina G., Augsornworawat, Punn, Hogrebe, Nathaniel J., & Millman, Jeffrey R. (2020). SIX2 
Regulates Human β Cell Differentiation from Stem Cells and Functional Maturation In Vitro. 




Generation of insulin-secreting β cells in vitro is a promising approach for diabetes cell therapy. 
Human embryonic stem cells (hESCs) and human induced pluripotent stem cells (hiPSCs) are 
differentiated to β cells (SC-β cells) and mature to undergo glucose-stimulated insulin secretion, 
but molecular regulation of this defining β cell phenotype is unknown. Here, we show that 
maturation of SC-β cells is regulated by the transcription factor SIX2. Knockdown (KD) or 
knockout (KO) of SIX2 in SC-β cells drastically limits glucose-stimulated insulin secretion in 
both static and dynamic assays, along with the upstream processes of cytoplasmic calcium flux 
and mitochondrial respiration. Furthermore, SIX2 regulates the expression of genes associated 
with these key β cell processes, and its expression is restricted to endocrine cells. Our results 
demonstrate that expression of SIX2 influences the generation of human SC-β cells in vitro. 
3.2 Introduction 
 
Pancreatic β cells regulate blood glucose levels by secreting a precise amount of insulin in 




diabetes. Transplantation of insulin-secreting cells shows promise to be an effective treatment for 
diabetes (McCall and Shapiro 2012; Millman and Pagliuca 2017a), and a small number of 
patients who have received such implants from cadaveric donors remain normoglycemic for 
years. Scarcity and high variability of donor islets limit this approach, however (McCall and 
Shapiro 2012). 
To overcome this limitation, strategies for specifying β cells from human embryonic stem cells 
(hESCs) in vitro have been described recently (Pagliuca et al. 2014; Rezania et al. 2014). These 
approaches use growth factors and small molecules to mimic native β cell development by first 
specifying definitive endoderm (D’Amour et al. 2005), followed by the generation of NKX6-
1+ pancreatic progenitors (Kevin A D’Amour et al. 2006). These progenitors are specified into 
endocrine via the expression of NEUROG3 (NGN3) (Gu, Dubauskaite, and Melton 2002) and 
are subsequently matured into SC-β cells and other islet endocrine cell types (Veres et al. 2019). 
More recent studies have defined conditions that greatly improve the functional maturation of 
SC-β cells, achieving first- and second-phase insulin secretion (Hogrebe et al. 2020; Velazco-
Cruz et al. 2019b). While a large number of genes that temporally correlate with maturation have 
been identified (Nair et al. 2019; Veres et al. 2019), the molecular mechanisms controlling this 
functional maturation are unclear, hampering further improvements in function. 
To investigate the functional maturation of human β cells in vitro, we studied the homeobox 
transcription factor SIX2 during differentiation to SC-β cells. SIX2 is not expressed in rodent β 
cells (Segerstolpe et al. 2016b; Xin et al. 2016), which limits the use of conventional approaches 
for its study, including commonly used insulinoma cell lines and animal models. SIX2 has 
recently been identified as being expressed in human β cells and linked to type 2 diabetes and 




Here, we report that SIX2 is key for generating functional SC-β cells in vitro. Using short hairpin 
RNA (shRNA) and CRISPR-Cas9 to knock down (KD) SIX2 expression or knock out (KO) 
the SIX2 gene, respectively, we show that both static and dynamic glucose-stimulated insulin 
secretion are severely hampered with reduced SIX2 expression. Upstream processes of 
cytoplasmic calcium flux and mitochondrial respiration are similarly reduced. Using RNA 
sequencing, we observe a large number of genes associated with maturation and β cell function 
to be reduced with the KD of SIX2, including gene sets associated temporally with SC-β cell 
maturation in vitro from other research groups. 
3.3 Results 
3.3.1 SIX2 Is Crucial for Acquisition of Glucose-Stimulated Insulin Secretion 
 
Since SIX2 is expressed in human β cells, but its regulatory role during β cell differentiation and 
maturation is uncharacterized, we measured its gene expression during our 6-stage differentiation 
protocol (Figure 3.1A). We observed a notably large increase in expression during the 
maturation of endocrine progenitors to SC-β cells (Figure 3.1B). Closer inspection of stage 6 
revealed that the gene expression of SIX2 increased 32.5 ± 0.9 times during the first 11 days, 
correlating with increases in insulin protein secretion per cell for the same time period 
(Figure 3.1C). 
To further study SIX2 using our SC-β cell platform, we generated 2 lentiviruses carrying 
shRNAs (sh-SIX2-1 and sh-SIX2-2) to KD the expression of SIX2 (Figures S3,1A and S3.1B). 
For these KD studies, we transduced cells on the first day of stage 6 to limit the emergence of 
SIX2 expression with time. KD of SIX2 in differentiating hESCs (HUES8) and human induced 




dynamic and static glucose-stimulated insulin secretion assays (Figures 3.1D, 3.1E, and S3.1C–
S1F). While peaks in the dynamic insulin secretion profile resembling first- and second-phase 
insulin secretion were still observed, the overall amount of insulin secreted per DNA was 4.2 ± 
1.2 times lower at high glucose with SIX2 KD (Figure 3.1D). Similarly, for the static assay, 
while the cells still responded, albeit more weakly, to glucose by secreting elevated insulin, 
insulin secretion per cell was 4.7 ± 0.8 times lower at high glucose with SIX2 KD (Figure 3.1E). 
We do note that the magnitude of the relative insulin secretion at low glucose differed between 
static and dynamic assays, perhaps due to fluid shear or paracrine effects. 
Since the KD studies supported a connection between SIX2 and the acquisition of SC-β cell 
function, we used CRISPR-Cas9 to KO SIX2 by deleting the SIX2 coding sequence to create 2 
homozygous KO hESC lines (KO-SIX2-1 and KO-SIX-2) to ensure the complete absence of 
SIX2 (Figures S3.1G–S3.1K). Similar to the KD studies, KO of SIX2 also resulted in significant 
reductions in both dynamic and static glucose-stimulated insulin secretion assays (Figures 3.1F 
and 1G). In contrast to the KD studies, SIX2 KO resulted in no first- and second-phase dynamic 
insulin responses to high glucose and no response to glucose in the static assay. In addition, the 
overall amount of insulin secreted per DNA was 4.2 ± 0.7 times lower in the dynamic assay and 
per cell was 6.2 ± 1.5 times lower in the static assay at high glucose for SIX2 KO (Figures 3.1F 
and 1G).  Arda et al. (2016) showed that SIX3, a different transcription factor within the SIX 
family, is enriched in adult human islets relative to juvenile islets and that its expression is 
associated with increased β cell function. We measured the expression profile of SIX3 during our 
SC-β cell differentiation (Figure S3.2A). While increased expression during early definitive 
endoderm induction was measured, SIX3 expression was low or undetected at the end of the 




establish SIX2 as a potent regulator of human β cell acquisition of functional maturation in vitro, 
demonstrating that SIX2 is necessary for first- and second-phase insulin secretion in response to 
glucose. SIX2 is not required for insulin production and secreting, but the lack of SIX2 reduced 
insulin secretion when cells are exposed to high glucose. 
3.3.2 Characterization of SIX2 Expression During SC-β Cell Differentiation 
 
Next, we characterized the expression profile of SIX2 protein throughout the differentiation 
process. Using immunofluorescence, we did not detect SIX2 expression in C-peptide+ cells at the 
beginning of stage 6, but after 11 days in stage 6, some C-peptide+ cells expressed nuclear SIX2 
(Figure 3.2A). Virtually all SIX2+ cells co-expressed NKX6-1 (Figure 3.2A). With flow 
cytometry, we demonstrated that 25.1% ± 0.5% of the C-peptide+ cells co-expressed SIX2 in 
stage 6 (Figure 3.2B). However, some SIX2+ cells were observed outside the C-
peptide+ population and are of unknown identity. We also observed that SIX2 was restricted to 
NKX2-2+ and synaptophysin+ (SYN) cells in stage 6 (Figure 3.2C), indicating that the expression 
of SIX2 is restricted to this endocrine cell population. In spite of this, SIX2 was not observed in 
NGN3+ cells during stage 5 (Figure 3.2C), even with many of these cells co-expressing NKX6-1 
(Figure S3.2C). Virtually all SIX2+ cells also co-expressed other pancreatic markers, such as 
ISL1, PAX6, and PDX1 (Figure 3.2C). Furthermore, the α cell hormone-expressing 
glucagon+ (GCG) cells did not express SIX2, and SOX9+ progenitors were absent in the stage 6 
population (Figure 3.2C). KD of SIX2 reduced the fraction of cells expressing C-peptide+ and 
co-expressing C-peptide with NKX6.1 (Figures 3.2D and S3.2D), demonstrating an effect on cell 




demonstrate that SIX2 protein expression is only detected in the endocrine population and 
influences final cell fate. 
3.3.3 Transcriptional Profiling of SIX2 KD cells 
 
To further explore the role of SIX2 on SC-β cells, we used RNA sequencing to measure the 
transcriptome of stage 6 cells transduced with shRNA to KD SIX2 expression. A large number 
(10,421) of genes were significantly (adjusted p < 0.05) affected by the KD of SIX2, including 
individual genes associated with β cell function and off-target non-β cell genes (Figures 
3.3 and S3.3). Of the significantly different genes, 633 were enriched in the control cells and 509 
were enriched in the SIX2 KD cells by at least a factor of 2 (Figure 3.3B). 
Several gene sets important for β cells, such as those correlated with β cell fate, β cell 
maturation, exocytosis, potentiation of insulin secretion, and maturation, were controlled by 
SIX2 (Figures 3.3C–3.3E, S3.3A, and S3.3B). The specific established gene sets that are well 
known included the gene sets β cell enriched (CARTPT, IAPP, GLP1R, GCK, ABCC8, PAX6, 
INS), calcium signaling (HPCAL4, CAMKK2A, CACNA1S), potassium channels (ATP1A3, 
KCNN3, KCNMA1), cyclic AMP (cAMP) signaling (ADCY8, CREB5, ADCY3), and protein 
kinase C (PKC) signaling (PRKC3, PRKCH, PRKCA). In addition, undesirable off-target 
markers, including liver (ALB, AFP), anterior endoderm (SOX2), and posterior endoderm 
(CDX2), and gene sets, such as glycolysis, were enriched in the SIX2 KD cells. We validated 
RNA sequencing results with a subset of relevant genes using real-time PCR in the 1013-4FA 
hiPSC background (Figure S3.3C). We compared our RNA sequencing data to recent gene sets 
identified in Veres et al. (2019) and Nair et al. (2019) as positively correlating with time in the 
final stage of differentiation of SC-β cells in vitro. We found that our SIX2 KD data were 




and S3.4). Specifically, the KD of SIX2 repressed many of the genes that increased expression 
in Veres et al. (2019) and Nair et al. (2019), suggesting that many of these identified genes are 
controlled by SIX2. These data support the conclusion that SIX2 controls the expression of many 
β cell genes related to normal physiological function and differentiation. 
3.3.4 Physiological Profiling of SIX2 KD SC-β Cells 
 
We followed up on key β cell processes implicated by the SIX2 KD RNA sequencing data. First, 
we found that KD of SIX2 reduced insulin content and INS gene expression, but it did not affect 
insulin processing (Figures 3.4A–3.4C and S3.4A). Second, we assessed mitochondrial 
respiration and glycolysis because switching from glycolysis to mitochondrial respiration is 
necessary for the maturation and normal physiological function of β cells (Nair et al. 2019). The 
Seahorse XFe24 extracellular flux assay was used to measure the oxygen consumption rate 
(OCR) and the extracellular acidification rate (ECAR), respectively. KD of SIX2 resulted in a 
decreased OCR and ratio of OCR to ECAR (Figures 3.4D, 3.4E, and 3.S4C). Cytoplasmic 
calcium flux was also evaluated, as the influx of calcium is necessary before insulin secretion 
and is triggered by glucose-induced depolarization in β cells (Rutter and Hodson 2013). KD of 
SIX2 slightly decreased glucose-stimulated and greatly decreased KCl-stimulated increases in 
cytoplasmic calcium as determined with Fluo-4 AM stained cells (Figure 3.4F). These data are 
consistent with decreased glucose-stimulated insulin secretion (Figures 3.1D–3.1G and S3.1C–
S3.1F) and the RNA sequencing analysis (Figure 3.3), indicating that SIX2 plays a key role in 
the metabolism and upstream signaling relating to the functional maturation of SC-β cells. 
Finally, we explored other known insulin secretagogues, observing that while SIX2 KD cells 
were able to respond to all treatments, the amount of insulin secretion was much lower than the 




demonstrated that SIX2 KD cells were capable of elevating insulin secretion, but glucose-
dependent secretion was severely impaired without SIX2. Furthermore, considering the large 
amount of insulin secretion with treatments targeting downstream processes, particularly 
depolarization (KCl) and cAMP accumulation (IBMX), upstream mechanisms appear more 
affected by SIX2 KD, namely glucose sensing and metabolism. In addition to defects in glucose-
stimulated insulin secretion, SC-β cells with KD of SIX2 have defects in insulin content, 
mitochondrial respiration, calcium signaling, and response to a wide array of secretagogues. 
3.4 Discussion 
 
Here, we demonstrate that SIX2 influences the generation human SC-β cells in vitro. Increases in 
SIX2 expression correlates with increases in insulin secretion as SC-β cells mature during stage 6 
of the differentiation protocols. KD or KO of SIX2 dramatically reduces glucose-stimulated 
insulin secretion, including first- and second-phase dynamic insulin release and the total amount 
of insulin released from the cells. Expression of SIX2 protein appears to be restricted to 
endocrine cells. RNA sequencing of cells with the KD of SIX2 reveals that a large number of 
gene sets associated with β cells and off-targets are negatively affected, including recently 
defined gene sets of maturing SC-β cells. We confirmed the physiological effects of many of 
these gene sets by measuring reductions in insulin content, insulin gene expression, 
mitochondrial respiration, calcium flux, and insulin secretion in response to compounds that 
block the KATP channel (tolbutamide), accumulate cAMP (IBMX), activate GLP1R (Exendin-4), 
and depolarize the membrane (KCl). 
A major goal in regenerative medicine is to generate fully mature replacement cells 
differentiated from stem cells. However, while many differences often exist in the function and 




specific to the differentiated cells in question, identifying specific parameters on which to focus 
is often difficult due to a lack of understanding of human developmental biology. In the case of 
SC-β cells, many genes and pathways have been focused on and studied in the context of 
improving these cells, including YAP (Rosado-Olivieri et al. 2019), the ROCKII pathway 
(Ghazizadeh et al. 2017), the transforming growth factor β (TGF-β) pathway (Velazco-Cruz et 
al. 2019b), and the cytoskeleton (Hogrebe et al. 2020). Further studies have connected diabetic 
pathogenetic variants with impairments in polyhormonal endocrine or SC-β cells, including INS 
(Balboa et al. 2018; Ma et al. 2018), HNF1-α (Cardenas-Diaz et al. 2019), WFS1 (Maxwell et al. 
2020a; Shang et al. 2014), ZNT8 (Dwivedi et al. 2019), NEUROD1 (Romer et al. 2019), and 
GCK (Hua et al. 2013). 
In contrast, here, we focus on the role of SIX2 in the differentiation to and maturation of SC-β 
cells and establish a critical connection between this transcription factor and the generation and 
functional maturation of SC-β cells, particularly regarding glucose-stimulated insulin 
secretion. Arda et al. (2016) studied both SIX2 and SIX3 in the human insulinoma EndoC-βH1 
cell line and found overexpressing SIX3 but not SIX2 to increase insulin secretion and content in 
addition to increased expression of these genes in adult versus juvenile islets, supporting 
differing roles for these transcription factors. Our study differs from that of Arda et al. (2016) in 
several respects. We studied SIX2 in the context of differentiating and maturing SC-β cells, the 
process of which has increasing SIX2 expression as cells mature with time, a considerably 
different developmental context than that modeled by EndoC-βH1 cells. Furthermore, our study 
investigates many other aspects of β cell phenotype not explored by Arda et al., including 
demonstrating that both first- and second-phase dynamic insulin secretion are eliminated with 




functional characterizations (Velazco-Cruz et al. 2019b), indexing transcriptional changes with 
KD of SIX2, and showing how mechanisms of β cell glucose sensing, respiration, and calcium 
flux are disrupted with KD of SIX2. Furthermore, while our data demonstrate the importance of 
SIX2 in SC-β cells, this transcription factor is in the presence of many other transcription factors 
that are important for the β cell phenotype, including PDX1, NKX6-1, NKX2-2, and NEUROD1 
(Hogrebe et al. 2020). Understanding the molecular interactions and regulatory network of SIX2 
with these transcription factors would be valuable in future studies. 
Differences in transcriptional regulation in rodent and human β cells are well known (Benner et 
al. 2014). Since SIX2 expression is restricted to human β cells (Segerstolpe et al. 2016a; Xin et 
al. 2016), focused studies on human cell model systems, such as that provided by 
our in vitro differentiation platform, are essential in the investigation of cell maturation and 
disease. Proper understanding of the molecular mechanisms that control human β cell maturation 
is necessary for developing further improvements in SC-β cell technologies for diabetes cell-
replacement therapies. As only a fraction of C-peptide+ cells currently express SIX2 in our study, 
increased co-expression could result in differentiated populations with increased function and 
utility for cell therapy. Further study into the role of SIX2 could reveal new insights into 
increasing the functional maturation of SC-β cells and the regulation of expression of other β cell 
genes, such as MAFA (Nair et al. 2019; Velazco-Cruz et al. 2019b), or β cell failure in type 2 
diabetes. 
3.5 Experimental Procedures 
 
Culture of undifferentiated hESCs and differentiation to Stage 6 cells 
Cell culture was performed as we previously described (Hogrebe et al. 2020; Millman et al. 




Washington University School of Medicine Embryonic Stem Cell Research Oversight 
Committee (ESCRO). The HUES8 hESC and 1013-4FA hiPSC lines was generously provided 
by Dr. Douglas Melton (Harvard University) and has been published on previously (Hogrebe et 
al. 2020; Velazco-Cruz et al. 2019b). All data is with the HUES8 cell line unless otherwise noted 
to be 1013-4FA. For differentiation protocol 1 (Velazco-Cruz et al. 2019b), which was used 
unless otherwise noted, undifferentiated HUES8 were cultured in mTeSR1 (StemCell 
Technologies; 05850) in 30-mL spinner flasks (REPROCELL; ABBWVS03A) on a rotator stir 
plate (Chemglass) at 60 RPM in a humidified 37°C 5% CO2 tissue culture incubator. Stem cells 
were passaged every 3 days by single cell dispersion using Accutase (StemCell Technologies; 
07920), viable cells counted with Vi-Cell XR (Beckman Coulter), and seeded at 6 × 105 cells/mL 
in mTeSR1+ 10 μM Y27632 (Abcam; ab120129). The media was then changed to induce 
differentiation. For differentiation protocol 2 (Hogrebe et al. 2020), which was used for the KO 
studies and 1013-4FA differentiations, undifferentiated pluripotent stem cells were cultured in 
mTeSR1 on plates coated with Matrigel (Corning; 356230) in a humidified 37°C 5% CO2 tissue 
culture incubator. Stem cells were passaged every 4 days single cell dispersion using TrypLE 
(Life Technologies; 12-604-039), viable cells counted with Vi-Cell XR, and seeded at 5.2 × 
105 cells/cm2 in mTeSR1+ 10 μM Y27632. On stage 6 day 1 of protocol 1 and stage 6 day 7 of 
protocol 2 cells were single cell dispersed using TrypLE (Life Technologies; 12-604-039; 15-
minute incubation for protocol 1, 6-minute incubation for protocol 2). Following single cell 
dispersion cells were re-aggregated by seeding 5 million cells in 5 mL of stage 6 media into a 
well of a 6-well plate placed on an orbi-shaker (Benchmark) rotating at 100 RPM; clusters were 





Measurements were performed as we previously described (Velazco-Cruz et al. 2019b). RNeasy 
Mini Kit (QIAGEN; 74016) with DNase treatment (QIAGEN; 79254) was used for RNA 
extraction. High Capacity cDNA Reverse Transcriptase Kit (Applied Biosystems; 4368814) was 
used to make cDNA. PowerUp SYBR Green Master Mix (Applied Biosystems; A25741) on a 
StepOnePlus (Applied Biosystems) was used to perform the real-time PCR reactions. Melting 
curves were ran for each primer to determine specificity of amplification. ΔΔCt methodology 
with TBP normalization was used for analysis. For samples undetected using real-time PCR CT 
values where set to 40 in analysis. Primer sequences used were (gene, forward primer, reverse 
primer): INS, CAATGCCACGCTTCTGC, TTCTACACACCCAAGACCCG; TBP, 
GCCATAAGGCATCATTGGAC, AACAACAGCCTGCCACCTTA; SIX2, 
AAGGCACACTACATCGAGGC, CACGCTGCGACTCTTTTCC; SIX3, 
CTGCCCACCCTCAACTTCTC, 
GCAGGATCGACTCGTGTTTGT; IAPP, ACATGTGGCAGTGTTGCATT, 
TCATTGTGCTCTCTGTTGCAT; UCN3, TGTAGAACTTGTGGGGGAGG, 
GGAGGGAAGTCCACTCTCG; ABCC8, GCCCACGAAAGTTATGAGGA, 
AAGGAGATGACCAGCCTCAG; GCK, ATGCTGGACGACAGAGCC, 
CCTTCTTCAGGTCCTCCTCC; GLP1R1, GGTGCAGAAATGGCGAGAATA, 
CCGGTTGCAGAACAAGTCTGT; HOPX, GAGACCCAGGGTAGTGATTTGA, 
AAAAGTAATCGAAAGCCAAGCAC; NEFL, ATGAGTTCCTTCAGCTACGAGC, 





CCTTTGGCACAATGAAGTGGGTAACC, CAGCAGTCAGCCATTTCACCATAGG; CDX2, 
CCTCTGAGATGCTGTCATGTAGT, GGTGATGTAGCGACTGTAGTGAA; AFP, 
TGTACTGCAGAGATAAGTTTAGCTGAC, CCTTGTAAGTGGCTTCTTGAACA 
KD of SIX2 
Gene KD was performed similar to as we previously described (Velazco-Cruz et al. 2019b). 
pLKO.1 TRC plasmids containing shRNA sequences targeting GFP (sh-ctrl) and human SIX2 
(sh-SIX2-1 and sh-SIX2-2) were received from the RNAi Core at the Washington University. sh-
ctrl, GCGCGATCACATGGTCCTGCT; sh-SIX2-1, CAACGAGAACTCCAATTCTAA; sh-
SIX2-2, GAGCACCTTCACAAGAATGAA. Viral particles were generated using Lenti-X 293T 
cells (Takara; 632180) cultured in DMEM (MilliporeSigma; D6429) with 10% heat inactivated 
fetal bovine serum (MilliporeSigma; F4135). Confluent Lenti-X 293T cells were transfected with 
6 μg of shRNA plasmid, 4.5 μg of psPAX2 (Addgene; 12260), and 1.5 μg pMD2.G (Addgene; 
12259) packaging plasmids in 600 μL of Opti-MEM (Life Technologies;31985-070) and 48 μL 
of Polyethylenimine ‘Max’ MW 40,000 Da (Polysciences; 24765-2). 16 hours post transfection 
media was switched. Viral containing supernatant was collected at 96 hours post transfection and 
concentrated using Lenti-X concentrator (Takara; 631232). Collected lentivirus was tittered 
using Lenti-X qRT-PCR Titration Kit (Takara; 631235). Lentiviral transduction occurred on the 
first day of Stage 6 by seeding 5 million dispersed single cells were into a well of a 6-well plate 
with lentivirus particles MOI of 5, media was switched 16 hours post transduction. psPAX2 and 
pMD2.G were a gift from Didier Trono. 
Generation of SIX2 KO cell lines 
CRISPR/Cas9 genome engineering of the HUES8 cell line was performed by the Washington 




genes limited the availability of high-quality gRNA sites, making conventional frameshift 
introduction infeasible. Instead, a deletion strategy was employed for almost all the SIX2 coding 
sequence. Unique genomic regions near the start and end of the SIX2 coding sequence were 
identified and guide RNAs were designed; 5′ gRNA, TCGGAGCTTCGTGGGACCCGCGG and 
3′gRNA, CCACGAGGTTGGCTGACATGGGG. Two homozygous SIX2 KO HUES8 cell lines 
were generated (KO-SIX2-1 and KO-SIX2-2). Validation of SIX2 KO was done by PCR using 
primers (GGGAGAACGAGTGAGAAGCG, TGCGGGTCTTTCAGTACCTG) designed to 
amplify a 3368 bp sequence containing the coding region, deletion of which will produce a 
∼300 bp amplicon (“Deletion primers”). Validation was also done using primers 
(CAGTTCTGGGAGAGAAGAGAC, GGGCTGGATTCTGTTCCCATA) targeting within the 
SIX2 coding sequence designed to amplify 300 bp in wt and failing to amplify with successful 
deletion (“Inside primers”). Next generation sequencing was performed to further confirm KO. 
Static glucose-stimulated insulin secretion 
Measurements were performed as we previously described (Velazco-Cruz et al. 2019b). The 
assay was performed in KRB buffer (128 mM NaCl, 5 mM KCl, 2.7 mM CaCl2 1.2 mM MgSO4, 
1 mM Na2HPO4, 1.2 mM KH2PO4, 5 mM NaHCO3, 10 mM HEPES (GIBCO; 15630-080), and 
0.1% BSA). Stage 6 clusters (∼20-30) were washed with KRB buffer and placed into transwells 
(Corning; 431752) with 2 mM glucose KRB. After 1 hr of equilibration, the solution was 
replaced with 2 mM glucose KRB for a 1 hr low glucose challenge, after which the solution was 
replace with 20 mM glucose alone or with 
10 nM Extendin-4 (MilliporeSigma; E7144), 100 μM IBMX (MilliporeSigma; I5879), 300 μM 




Fisher; BP366500) KRB for a 1 hr high glucose challenge. Incubations were performed in a 
humidified incubator at 37°C 5% CO2. Insulin was quantified with a human insulin ELISA 
(ALPCO; 80-INSHU-E10.1). Cell quantification was performed by dispersing with trypLE and 
counting with the Vi-Cell XR. 
Dynamic glucose-stimulated insulin secretion 
Measurements were performed as previously described (Velazco-Cruz et al. 2019b). Using an 8-
channel peristaltic pump (ISMATEC; ISM931C) together with 0.015” inlet/outlet two-stop 
tubing (ISMATEC; 070602-04i-ND) connected to 275-μl cell chamber (BioRep; Peri-Chamber) 
and dispensing nozzle (BioRep; PERI-NOZZLE) using 0.04” connection tubbing (BioRep; Peri-
TUB-040). Solutions, tubing, and cells were maintained at 37°C using a water bath. Stage 6 
clusters (∼20-30) were washed with KRB buffer and placed into perifusion cell chamber 
between two layers of hydrated Bio-Gel P-4 polyacrylamide beads (Bio-Rad; 150-4124). After 
90 min of equilibration with 2 mM glucose KRB, cells were subjected to the following at 
100 μL/min: 12 min of 2 mM glucose KRB, 24 min of 20 mM glucose KRB, and finally 12 min 
of 2 mM glucose KRB. Effluent was collected every 2 min. Insulin was quantified with a human 
insulin ELISA (ALPCO; 80-INSHU-E10.1). DNA quantification was performed by lysing the 
cells and measuring with the Quant-iT Picogreen dsDNA assay kit (Invitrogen; P7589). The lysis 
solution used consisted of 10 mM Tris (MilliporeSigma; T6066), 1 mM EDTA (Ambion; 
AM9261), and 0.2% Triton X-100 (Acros Organics; 327371000). 
Immunostaining 
Measurements were performed as we previously described (Velazco-Cruz et al. 2019b). Stage 6 
clusters were single-cell dispersed with trypLE, plated overnight, and fixed with 4% 




treated for 30 min with blocking/permeabilizing/staining solution (5% donkey serum (Jackson 
Immunoresearch; 017-000-121) and 0.1% Triton X-100 (Acros Organics; 327371000) in PBS). 
Samples were then incubated overnight at 4°C with primary antibody diluted in staining solution, 
incubated 2 hr at 4°C with secondary antibodies diluted in staining solution, and stained with 
DAPI for 5 min. Nikon A1Rsi confocal microscope or Leica DMI4000 fluorescence microscope 
were used to take images.  
Flow cytometry 
Measurements were performed as we previously described (Velazco-Cruz et al. 2019b). Clusters 
were single-cell dispersed with TrypLE, fixed with 4% paraformaldehyde for 30 min at 4°C, 
incubated 30 min at 4°C in blocking/permeabilizing/staining solution, incubated with primary 
antibodies in staining buffer overnight at 4°C, incubated with secondary antibodies in staining 
buffer for 2 hr at 4°C, resuspended in staining buffer, and analyzed on an LSRII (BD 
Biosciences) or X-20 (BD Biosciences). Dot plots and percentages were generated using FlowJo.  
RNA sequencing 
RNA from sh-ctrl and sh-SIX2-1 transduced cells (n = 6 per condition) was extracted on Stage 6 
Day 12 using RNeasy Mini Kit with DNase treatment. Washington University Genome 
Technology Access Center performed library preparation, sequencing, and determination of 
differential expression. Libraries were indexed, pooled, and single-end 50 base pair reads were 
sequenced on one lane of an Illumina HiSeq 3000 generating 25-30 million reads per sample. 
Reads were then aligned to the Ensembl release 76 top-level assembly with STAR. Gene counts 
were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount. 
All gene counts were imported into EdgeR5 and TMM normalization size factors were 




samples greater than one count-per-million were excluded from further analysis. The TMM size 
factors and the matrix of counts were imported into Limma6. Weighted likelihoods based on the 
observed mean-variance relationship of every gene and sample were calculated for all samples 
with the voomWithQualityWeights7. Differential expression analysis was performed with a 
Benjamini-Hochberg false-discovery rate adjusted p values cut-off of less than or equal to 0.05. 
Hierarchical clustering and heatmaps were generated using Morpheus 
(https://software.broadinstitute.org/morpheus). To perform gene set enrichment analyses 
normalized all gene counts were imported into GSEA software and the Molecular Signature 
Database (MSigDB) Hallmark, KEGG, and Gene Ontology gene libraries were used to identify 
enriched gene sets (Subramanian et al. 2005). In Vitro Beta Cell Maturation gene set was 
generated by combining Veres et al. (Veres et al. 2019) Stage 6 enriched genes logbase2 fold or 
greater (76 genes), and Nair et al. (Nair et al. 2019) β-clusters enriched genes (424 genes) with 
SIX2 removed. 
Hormone content measurements 
Measurements were performed as we previously described (Velazco-Cruz et al. 2019b). Stage 6 
cell clusters were collected, washed with PBS, placed in acid-ethanol solution (1.5% HCl and 
70% ethanol), stored at −20°C for 24 hours, vortexed, returned to −20°C for 24 additional hours, 
vortexed, and centrifuged at 2100 G for 15 min. The supernatant was collected and neutralized 
with an equal volume of 1 M TRIS (pH 7.5). Human insulin and pro-insulin content were 
quantified using Human Insulin ELISA and Proinsulin ELISA (Mercodia; 10-1118-01) 
respectively. Samples were normalized to cell counts made using the Vi-Cell XR. 




Measurements were performed similar to as we previously reported (Millman et al. 2019). Stage 
6 cell clusters were dispersed into a single-cell suspension and plated 200,000 per well. After 
overnight incubation in S6 media, the media was replaced with RPMI-1640 (Sigma; R6504) with 
7.4 pH and 20 mM glucose. The Seahorse XFe24 flux analyzer (Agilent) was used to measure 
OCR and ECAR. After basal measurements, 3 μM oligomycin (Calbiochem; 1404-19-9), 
0.25 μM carbonyl cyande-4-(trifluoromethoxy) phenylhydrazone (FCCP) (Sigma; 270-86-5), 
and 1 μM rotenone (Calbiochem; 83-79-4) and 2 μM antimycin A (Sigma; 1397-94-0) where 
injected sequentially and replicate measurements performed. 
Cytoplasmic calcium measurements 
Calcium measurements were done similar as previously reported (Kenty and Melton 2015; 
Pagliuca et al. 2014). Stage 6 day 12 clusters were single cell dispersed by incubation in TrypLE 
for 10 minutes and plated down onto a Matrigel coated #1.5 glass bottom 96 well plate (Cellvis; 
963-1.5H-N) and allowed to attach overnight. Following overnight attachment clusters were 
washed twice with 2 mM glucose KRB and incubated in 2 mM glucose KRB with 20 μM Fluo-4 
AM (Invitrogen; F14201) for 45 min at 37°C. Cells were washed twice with 2 mM glucose 
KRB, placed in 2 mM glucose KRB and incubated for 10 min at 37°C, then placed in a 37°C 5% 
CO2 humidified Tokai-hit stage-top on a Nikon Eclipse Ti inverted spinning disk confocal 
equipped with a Yokagawa CSU-X1 variable speed Nipkow spinning disk scan head equipped 
with a motorized xy stage including nano-positioning piezo z-insert. Images were acquired with 
the cells at 2 mM glucose KRB, 20 mM glucose KRB, and 20 mM glucose 30 mM KCl KRB. 
Analysis of calcium flux image stack was performed using ImageJ with the StackReg package 
for correction. 




GraphPad Prism was used to calculate statistical significance for all non-RNA sequencing data. 
One- or two-sided paired or unpaired t tests were used. 
Differential expression analysis of RNA sequencing data was performed with a Benjamini-
Hochberg false-discovery rate adjusted p values cut-off of less than or equal to 0.05. 
Error bars represent s.e.m. unless otherwise noted. Sample size (n) is specified in each figure 
caption and indicates biological replicates unless otherwise noted. Statistical parameters are 












Figure 3.1. SIX2 Controls Glucose-Stimulated Insulin Secretion in Human SC-β Cells 
(A) Schematic of hESC differentiation process. 
(B) Real-time PCR measurements of SIX2 in undifferentiated hESCs and at the end of each 
stage of the differentiation. Data are presented as the fold change relative to stage 6 cells. n = 3. 
(C) Real-time PCR measurements of SIX2 as a function of time in stage 6 plotted against insulin 
secretion of sampled cells placed in 20 mM glucose for 1 h. n = 4. 
(D) Dynamic glucose-stimulated insulin secretion of stage 6 cells transfected with control 
shRNA (sh-ctrl; n = 3) or shRNA targeting SIX2 (sh-SIX2-1; n = 4). Cells are perfused with 
2 mM glucose, except when indicated, in a perifusion chamber. 
(E) Static glucose-stimulated insulin secretion of sh-ctrl or sh-SIX2-1 transduced stage 6 cells. 
n = 4. 
(F) Dynamic glucose-stimulated insulin secretion of wild-type (WT) (n = 4), KO-SIX2-1 (n = 3 
technical replicates), or KO-SIX2-2 (n = 3 technical replicates) stage 6 cells. 
(G) Static glucose-stimulated insulin secretion of WT, KO-SIX2-1, or KO-SIX2-2 stage 6 cells. 
n = 4. 
All data in (B)–(E) were generated with cells from protocol 1 and all data in (F) and (G) were 
generated with cells from protocol 2. 
∗p < 0.05, ∗∗p < 0.01, ∗∗∗∗p < 0.0001 by 2-way paired (for low-high glucose comparison) or 








Figure 3.2. Subtypes of Differentiated Stage 6 Cells Express SIX2 
(A) Immunostaining of SIX2 with the β cell markers NKX6-1 and C-peptide at the end of stages 
5 (left) and 6 (right). 
(B) Flow cytometric quantification of co-expression of C-peptide with SIX2. n = 4. 
(C) Immunostaining of SIX2 with a panel of pancreatic markers at the end of stage 6 with the 
exception of NGN3/SIX2, which was stained 3 days into stage 5. 
(D) Flow cytometric quantification of stage 6 cells staining for C-peptide, NKX6.1, and 
chromogranin A using sh-ctrl and sh-SIX2-1 transduced cells. n = 6. ∗∗∗p < 0.001 by 2-way 
unpaired t test. 
(E) Schematic summary of marker progression in stages 5 and 6. 





Figure 3.3. SIX2 Regulates Important β Cell Genes and Gene Sets 
(A) Heatmap of 1,000 most differentially expressed genes between stage 6 cells transduced with 
sh-ctrl and sh-SIX2-1 by p value. n = 6. 
(B) Volcano plot showing all differentially expressed genes. Genes with at least a 2-fold change 
(FC) are in black. Genes of particular interest are highlighted. 
(C) Selected enriched gene sets for important β cell processes from the Molecular Signatures 




(2019) and the top 424 genes identified in Nair et al. (2019) positively correlating with time and 
maturation in vitro. NES, normalized enrichment score. 
(D) Enrichment plots from the shown gene sets. 
(E) FCs from genes within enriched β cell-related gene sets. 
 
Figure 3.4. SIX2 Affects Insulin Content, Mitochondrial Respiration, Cytoplasmic Calcium 
Flux, and Response to Secretagogues in SC-β cells 
(A) Insulin content for stage 6 cells. n = 12. ∗∗∗∗p < 0.0001 by 2-way unpaired t test. 
(B) Proinsulin:insulin content ratio for stage 6 cells. n = 12. ns (non-significant) by 2-way 
unpaired t test. 
(C) Real-time PCR measurements of INS gene expression for stage 6 cells. n = 4. ∗p < 0.05 by 2-
way unpaired t test. 
(D) OCR measurements under basal conditions and after sequential injections of oligomycin 
(OM), carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone (FCCP), and antimycin A with 




(E) Calculated OCR:ECAR ratio under basal conditions. n = 10 for sh-ctrl and n = 9 for sh-
SIX2-1. ∗∗∗∗p < 0.0001 by 2-way unpaired t test. 
(F) Cytosolic calcium signaling in response to high glucose (20 mM) and high KCl (30 mM) 
treatment relative to low glucose (2 mM, Fo) for Fluo-4 AM. Violin plots show distribution of 
cellular responses for sh-ctrl (n = 232) and sh-SIX2-1 (n = 276) transduced cells with median 
and quartiles marked with dashed lines. ∗∗∗∗p < 0.0001 by 2-way unpaired t test. 
(G) Static glucose-stimulated insulin secretion with cells with 2 mM glucose, 20 mM glucose, or 
20 mM glucose with the indicated compound. n = 3. ns, ∗∗ or ††p < 0.01, ∗∗∗ or †††p < 
0.001, ∗∗∗∗ or ††††p < 0.0001 by 2-way unpaired t test. ∗ indicates comparison within same 
compound treatment. † indicates comparison with low glucose with same shRNA treatment. 




3.7 Supplemental Figures 
 
Figure S3.1. Validation of SIX2 KD and KO assessments. Related to Figure 3.1. (A) Real-
time PCR measurements of SIX2 gene expression for Stage 6 cells transduced with sh-ctrl, sh-
SIX2-1, or sh-SIX2-2 for differentiated HUES8 (left) or 1013-4FA, made with protocol 2, (right) 




transduced with sh-ctrl or sh-SIX2-1 in the 1013-4FA background. (C) Dynamic 
glucosestimulated insulin secretion of Stage 6 HUES8 cells transfected with control shRNA (sh-
ctrl; n=4) or shRNA targeting SIX2 (sh-SIX2-2; n=4). Cells are perfused with 2 mM glucose 
except when indicated in a perifusion chamber. (D) Static glucose-stimulated insulin secretion of 
sh-ctrl or sh-SIX2-2 transduced Stage 6 HUES8 cells. n=5. (E) Dynamic glucose-stimulated 
insulin secretion of Stage 6 1013-4FA cells made with protocol 2 transfected with control 
shRNA (sh-ctrl; n=4) or shRNA targeting SIX2 (sh-SIX2-1; n=4). Cells are perfused with 2 mM 
glucose except when indicated in a perifusion chamber. (F) Static glucose-stimulated insulin 
secretion of sh-ctrl or sh-SIX2-1 transduced Stage 6 1013-4FA cells made with protocol 2. n=5. 
(G) CRISPR knock out strategy for the generation of the SIX2 KO HUES8 cell lines KO-SIX2-1 
and KO-SIX2-2. HUES8 homozygous SIX2 KO clones were generated by deleting the SIX2 
coding sequence using two gRNAs target flanking regions of the SIX2 coding sequence. Also 
shown are the primers used to validate deletion, “deletion primers” and “inside primers”. (H) 
PCR of SIX2 KO clones confirming SIX2 coding sequence deletion. “Deletion primers” will 
produce 3368 bp amplicon for wt but only ~300 bp amplicon with successful deletion. “Inside 
primers” will produce ~300 bp amplicon for wt but fail to amplify with successful deletion. (I) 
Next generation sequencing confirming deletion of SIX2 coding sequence in KO cell lines. The 
entire sequence between the 5’ and 3’ gRNA was absent (marked with red dash in reference). 
1,085 total reads for KOSIX2-1 clone and 840 total reads for KO-SIX2-2 clone were sequenced 
and 0% wt gRNA target sequence were detected and frame shifting indels totaled 100% for both 
clones. A few bp of SIX2 coding are leftover. (J) Real-time PCR measurements of SIX2 gene 




n=5. (K) C-peptide and SIX2 immunostaining of Stage 6 cells made with protocol 2 from wt or 
KO SIX2 HUES8 backgrounds. Error bars represent s.e.m. 
 
Figure S3.2. Additional evaluation of SIX3 and SIX2. Related to Figure 3.2. (A) Real-time 
PCR measurements of SIX3 in undifferentiated hESCs and at the end of each stage of the 
differentiation. Data is presented as the fold change relative to Stage 6 cells. All n=6, except PP2 
n=3. (B) Real-time PCR measurements of SIX3 gene expression for Stage 6 cells transduced 
with sh-ctrl or sh-SIX2-1 (n=4; left) or SIX2 wt and KO cells (n=5; right). ns=p>0.05. (C) 
Immunostaining of NGN3 and NKX6-1 3 days into Stage 5. Scale bar=25 μm. (D) Flow 
cytometry plots of Stage 6 cells made with protocol 2 from the 1013-4FA background transduced 
with shRNA against GFP (control) and SIX2. (E) Flow cytometry plots of Stage 5 day 1 cells 
made with protocol 2 from the HUES8 background wt or KO for SIX2. n=4. ns by unpaired two-





Figure S3.3. Additional RNA sequencing analysis. Related to Figure 3.3. (A) Enriched gene 
sets for important β cell processes from the Molecular Signatures Database. (B) Additional 




76 genes identified in Veres et al (Veres et al., 2019) and the top 424 genes identified in Nair et 
al (Nair et al., 2019) positively correlating with time and maturation in vitro (Tables S2-S3). (C) 
Real-time PCR measurements of Stage 6 cells made with protocol 2 transduced with sh-ctrl or 
sh-SIX2-1 in the 1013- 4FA background. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 by 
two-way unpaired t test. Error bars represent s.e.m. 
 
Figure S3.4. Additional data on SIX2 KD and KO effects on SC-β cells. Related to Figure 
3.4. (A) Insulin content for Stage 6 cells transduced with sh-ctrl or sh-SIX2-1 in the 1013-4FA 
background. n=5. (B) Insulin content for Stage 6 cells wt or KO for SIX2. n=5. (C) OCR 
measurements for Stage 6 cells transduced with sh-ctrl or sh-SIX2-1 in the 1013-4FA 
background under basal conditions and after sequential injections of Oligomycin (OM), 
Carbonyl cyanide4-(trifluoromethoxy)phenylhydrazone (FCCP), and Antimycin A with rotenone 
(AA/R). n=9 for sh-ctrl and n=10 for sh-SIX2-1. *p<0.05,***p<0.001 by two-way unpaired t 
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Cryopreserved Stem Cell-Derived Islets 




Stem cell-derived islets (SC-islets) have direct applications for diabetes disease modeling and 
treatment. SC-islet functional profiles approach that of primary islets and can be generated in 
indefinite amounts. However, SC-islets don’t proliferate, and their function is fleeting making 
their biobanking necessary. Here we present a method for the cryopreservation of SC-islets and 
characterize its effect on their biology. The cryopreserved SC-islets are comparable to their non-
cryopreserved controls in terms of their functional, metabolic, and transcriptomic profiles. These 
finding will help facilitate the research and translation of SC-islets. 
4.2 Introduction 
 
T1D is an autoimmune disease characterized by the destruction of insulin secreting  cells 
located within the islet of Langerhans (islet) (Gillespie 2006). Islets are responsible for the 
proper endocrine regulation of blood glucose and their dysregulation result in diabetes mellitus. 
The study of diabetes is limited by the lack of human tissue for disease modeling and its 
application towards cell therapies (Balboa & Otonkoski, 2015; Velazco-Cruz, Goedegebuure, & 
Millman, 2020). Transplantation of human cadaveric islets have been shown to regulate diabetes 
in human transplant subjects (Barton et al. 2012; Bellin et al. 2012), however such therapies are 
limited as proof-of-concept due to a reliance on rare cadaveric islet availability (Millman and 




surrogates of primary islets, several protocols have been published for the generation of stem 
cell-derived islets (SC-islets) (Velazco-Cruz, Goedegebuure, & Millman, 2020).  
SC-islets are coming into vogue with applications towards disease modeling and the 
development of diabetes cell therapies. Current SC-islet differentiation strategies are scalable, 
with potential to generate an indefinite supply of islets capable of secreting insulin in response to 
glucose and other islet secretagogues. Although differences remain, functional and 
transcriptomic profiles of SC-islets resemble that of primary islets. Several groups have 
successfully used SC-islets for disease modeling (Leite et al. 2020; Maxwell and Millman 2021), 
islet proliferation studies (Rosado-Olivieri et al. 2020), and the development of islet cell 
therapies (X. Wang et al. 2021). SC-islets have significant potential to facilitate or become the 
next generation of diabetes treatments. 
A conserved property between primary and SC-islets is their post-mitotic nature. Their lack of 
proliferation is ordinary and consequential to their functional maturity (Arda et al. 2016). 
However, their non-proliferative nature and dynamic/fleeting function during in vitro culture 
limits their experimental window(Velazco-Cruz et al. 2019a). Their limited experimental 
window, high differentiation-skill barrier, lengthy differentiation (30> days), and need for 
biobanking makes development and characterization of SC-islet cryopreservation technologies 
consequential to the field. Early cryopreservation strategies focused on the cryopreservation of 
stem cell-derived pancreatic progenitors, a developmental intermediate population (Konagaya 
and Iwata 2019; Trott et al. 2017). More recently, (P. Wang et al. 2018) and (Stock et al. 2019) 
have reported use of cryopreserved SC-islets. However, their cryopreservation methodology was 




Here, we report a SC-islet cryopreservation strategy and characterize the biological effects on 
SC-islets. We show that cryopreserved islets have comparable glucose stimulated insulin 
secretion (GSIS) to their controls. Single-cell RNA-sequencing reveals comparable 
transcriptomes between cryopreserved and their non-cryopreserved controls. Upon 
transplantation into immune compromised diabetic mice, the cryopreserved SC-islets are able to 
cure diabetes and secrete insulin comparable to their controls. Further characterization of 
cryopreserved SC-islets reveals similar insulin content, metabolic profile, and secretagogue 
response as their non-cryopreserved controls.  
4.3 Results 
4.3.1 Cryopreserving SC-islets 
We set out to cryopreserve SC-islets generated with our 6-stage differentiation protocol 
(Hogrebe et al. 2020). The SC-islet differentiation protocol guides human pluripotent stem cells 
(hPSC’s) through endodermal and pancreatic developmental intermediates using defined small 
molecules mimicking islet in vivo development. The resulting SC-islets undergo robust GSIS and 
cure diabetes in mice (Hogrebe et al. 2020). To cryopreserve SC-islets we took advantage of a 
unique endocrine enrichment approach utilized by current SC-islet differentiation protocols 
(Baron et al. 2016b; Hogrebe et al. 2020; Nair et al. 2019; Velazco-Cruz et al. 2019a). SC-islets 
are single cell-dispersed and re-aggregated in suspension culture, this generates endocrine 
enriched islet clusters resulting in improved SC-islet function (Hogrebe et al. 2020; Velazco-
Cruz et al. 2019a). Our SC-islet cryopreservation strategy takes the single-cell dispersed islets 




post thaw (Figure 4.1A).  By cryopreserving islet cells as single cells, penetration of 
cryoprotectant into clusters is not an issue.  
 
Cryopreserved SC-islets display expression of  cell markers C-peptide, NKX6.1, and CHGA 
(Figure 4B). 3-days post thaw islet aggregation is complete, clusters have smooth edges and 
morphology is comparable to their non-cryopreserved counterparts (Figure 4.1C). 
Cryopreservation of SC-islets reduces viable cell recovery (Figure 4.1D). Non-cryopreserved 
islets have an average aggregation viable cell recovery of 43.3% ±1.58% (mean ± SD; n = 4 
differentiations) while their cryopreserved counterparts present nearly half the recovery 22.9% ± 
0.66% (mean ± SD; n = 8 differentiations). No significant difference in cell recovery was 
observed when freezing in a Mr. Frosty or controlled rate freezer (Figure 4.1C,D). Despite a 
reduction in cell recovery the overall  cell population ratio, presumed to be C-
peptide+/NKX6.1+ co-expressing cells, is not harmed (Figure 4.1E,F). Flow cytometry analysis 
show NKX6.1 and CHGA expressing populations increase in cryopreserved islets relative to 
their controls, indicating further enrichment of endocrine cells. This increased enrichment is 
likely due to the added stress from cryopreservation, which non-endocrine cells are more 
susceptible to (Velazco-Cruz et al. 2019a). Glucagon and somatostatin expressing populations 
are reduced in cryopreserved islets. This loss is driven by a reduction in the polyhormonal 
populations (Figure S4.1A,B). Real-time PCR analysis shows a reduction in somatostatin and 
glucagon genes with a general enrichment of endocrine genes (Figure S4.1C). In vitro GSIS is 
comparable between control and cryopreserved islets (Figure 4.1G,H). Batch-matched AN1.1 




and 1 year were assessed by in vitro GSIS and % viable cell recovery assays. Length of time in 
liquid nitrogen storage did not affect function or cell recovery rates (Figure S4.1D,E).  
 
The (Hogrebe et al. 2020) protocol differentiates hPSC’s to SC-islets in an adherent culture 
format, facilitating culture of hPSC’s and the technical accessibility of the differentiation. 
However, large production batches necessary for cryobanking and uniformity will benefit from 
scalable suspension differentiation systems (Nair, Tzanakakis, and Hebrok 2020). We confirmed 
our cryopreservation methodology using the (Velazco-Cruz et al. 2019a) suspension 
differentiation protocol. Stage 6 Day 1 immature SC-islet clusters where single cell dispersed 
and cryopreserved. Upon thaw and aggregation viable cell recovery was similar to cryopreserved 
cells using the adherent differentiation protocol (Figure 4.1F, Figure S4.1D). Suspension derived 
cryopreserved SC-islets had similar GSIS relative to their non-cryopreserved controls (Figure 
4.1G,H).  
4.3.2 Functional Characterization of Cryopreserved SC-islets 
To better understand the functional effects of SC-islet cryopreservation insulin content, 
proinsulin content, metabolic respiration, islet secretagogue induced insulin secretion, and 
viability upon stress were assessed. Total insulin content is comparable between cryopreserved 
islets and their controls (Figure 2A). Proinsulin content is lower in cryopreserved SC-islets 
making their proinsulin-to-insulin ratio lower (Figure 2B). A lower proinsulin-to-insulin ratio 
indicates improved insulin processing indicative of higher functional maturity. This is likely due 




cryopreserved islets (Figure 1E,F and Figure S1A,B). Seahorse was used to assess metabolic 
respiration. Metabolic capacity was similar between cryopreserved SC-islets and their controls. 
OCR/ECAR ration is slightly higher in cryopreserved cells indicating improved mitochondrial 
respiration over anaerobic glycolysis. SC-islets have a high reliance on mitochondrial respiration 
to meet energy demands (Nair et al. 2019). Insulin secretion in response to multiple islet 
secretagogues glucose, IBMX, Extendin-4, tolbitamide, and KCl were comparable in terms of 
insulin secretion and stimulation index (Figure 2E,F). IBMX is a cytosolic cAMP agonist, 
exending-4 is a GLP-1 receptor agonist, tolbutamide is a sulfonylurea, and KCl acts as a 
membrane depolarizer. Apoptotic rate was measured in SC-islets treated with a pro-
inflammatory cytokine mixture (CM) or thapsigargin, an endoplasmic reticulum stressor. 
Cryopreserved and control SC-islets had similar apoptotic rates upon CM or thapsigargin 
treatment (Figure 2G,H). CM treatment significantly increased apoptotic rate similarly in control 
and cryopreserved SC-islets (Figure 2G). 10uM thapsigargin treatment did not significantly 
increase apoptotic rate and basal rates are similar between control and cryopreserved SC-islets 
(Figure 2H). Longer or higher thapsigargin concentrations should be run to observe a stress 
effect on SC-islets. As assessed, in vitro functional assessment of cryopreserved SC-islets is 
similar to their non-cryopreserved counterparts.  
4.3.3 Single-cell RNA sequencing reveals similar transcriptomic profiles 
between cryopreserved and control SC-islets 
Single-cell RNA sequencing (scRNA-seq) was used to compare cryopreserved and control SC-
islet transcriptomes at the individual population level (Figure 4.3). Sc-RNA seq was performed 




Hao et al. 2021; Satija et al. 2015; Stuart et al. 2019). UMAP clustering of cryopreserved and 
control SC-islets show ,, and  populations, respectively enriched with insulin, glucagon, and 
somatostatin expression ed (Figure 4.3A,B). TPH1 expressing enterochromaffin-like cells (EC) 
are identified in both conditions (Figure 4.3A,B). EC cells exist as off-targets in SC-islet 
differentiations and are absent from primary islets (Augsornworawat et al. 2020; Veres et al. 
2019). Enrichment of the β cell population (27% vs 20%) and depletion of the α cell population 
(32% vs 20%) was observed in cryopreserved SC-islets (total cells: 1,918) relative to control SC-
islets (total cells: 3209) (Figure 4.1C). This enrichment data supports flow cytometry and real-
time PCR observations (Figure 4.1E,F and Figure S4.1A,B). Differential expression analysis 
within the β cell population show similar transcriptional profiles between cryopreserved and 
control conditions (Figure 4.3D,E,F). Visualized with a volcano plot, no genes meet our 
combined significance cut-off of -Log10P value <15 and Log2FC of 1 (Figure 4.3D). A heat map 
of the top 1000 variables show that they are not driven by condition (Figure 4.3E). Comparison 
of key identity genes shows similar expression levels between cryopreserved and control SC-
islets (Figure 4.3F). Insulin, glucagon, and somatostatin expression levels are comparable in their 
respective cell types. General endocrine genes chromogranin a and PAX6 expression levels are 
similar.  cell maturation markers IAPP and HOPX (Augsornworawat et al. 2020; Veres et al. 
2019) are similarly expressed and MAFA expression is largely undetected. Ultimately, scRNA-
seq analysis reveal transcriptional similarity between cryopreserved and SC-islets cells.  
4.3.4 Transplanted cryopreserved SC-islets function in vivo 
Having established similar functional and transcriptomic profiles between cryopreserved and re-




control SC-islets were transplanted into the kidney capsule of immune compromised mice and 
rendered diabetic 1-month post transplantation using streptozocin. Two weeks post streptozocin 
induced diabetes random blood glucose was measured. Cryopreserved SC-islets recipient mice 
show similar blood glucose concentrations (227 ± 37 mg/dl) to their re-aggregated control 
counterparts (181 ± 43 mg/dl), while un-transplanted mice showed significantly higher diabetic 
blood glucose levels (537 ± 23 mg/dl) (Figure 4.4B). Human c-peptide was measured in 
transplanted mice showing similar levels between cryopreserved and re-aggregated control 
recipient mice, 450 ± 97 and 335 ± 34 pmol/L respectively (Figure 4.4C). Notably, the 
coefficient of variance is lower in cryopreserved recipients (20) than reaggregated control 
recipients (43) indicating improved transplant uniformity. In vivo GSIS is comparable between 
cryopreserved and re-aggregated control recipient mice with an average c-peptide concertation of 
468 ± 64 and 407 ± 31 pmol/L with stimulation indexes of 1.6 (Figure 4.4D,E). We performed a 
glucose tolerance test on transplanted and un-transplanted diabetic mice. Cryopreserved and re-
aggregated control SC-islet recipient mice show similar glucose regulation, while non-
transplanted mice present significantly higher blood glucose levels as assessed by are under the 
curve assessments (Figure 4.4F). This data shows cryopreserved SC-islets have equivalent 
glucose regulating potential as assessed by transplantation into diabetic mice.  
4.4 Discussion 
 
Here we demonstrate a method for cryopreserving SC-islets and investigate cryopreservation 
effects on their biology. By taking advantage of the aggregation properties of endocrine islet 
cells (Nair et al. 2019; Velazco-Cruz et al. 2019a; Veres et al. 2019), immature SC-islets cells are 
cryopreserved as single cells and aggregated into mature islet organoids upon thaw. The 




SST. Slight enrichment of endocrine cells and a reduction in polyhormonal cells is observed 
relative to the non-cryopreserved SC-islets. Functionally, cryopreserved SC-islets behave 
similarly to their non-cryopreserved counterparts. In vitro GSIS assays show similar insulin 
secretion between cryopreserved SC-islets and their non-cryopreserved counterparts. 
Secretagogue induced insulin secretion was similar between cryopreserved islets and their 
controls, indicating the insulin secretory mechanisms are comparable between conditions. Total 
stored insulin content is comparable between conditions, however proinsulin content is lower in 
cryopreserved cells. This is likely due to a reduction in the polyhormonal population, which 
show reduced insulin processing (Pagliuca et al. 2014) . Metabolic oxygen consumption capacity 
and apoptosis rates in response to cytokine or thapsigargin stressors are similar between 
conditions. Transcriptomic profiles are similar between cryopreserved and control SC-islets as 
assessed by scRNA-seq. Cryopreservation via Mr. Frosty or controlled rate freezer yielded 
similar results, meaning one must not possess an expensive controlled rate freezer for this 
methodology. SC-islets manufactured from both adherent or suspension differentiation protocols 
can be cryopreserved using the methodology presented here. Cryopreserved SC-islets biobanked 
in liquid nitrogen for a year show similar functional profiles and viable recovery rates relative to 
those biobanked for 48hrs, this shows the longevity of cryopreserving and biobanking of SC-
islets.  
A major application of SC-islets is their use in the development of diabetes cell therapeutics. In 
vivo functional potential was assessed by transplantation into immune compromised diabetic 
mice resulting in similar glucose regulatory capacity between cryopreserved and control SC-
islets. Here, we transplant a sub-therapeutic dose of SC-islets, 2 million cells, and see strong 




levels remain above 200 mg/dl. To better evaluate therapeutic cure potential a sufficient number 
of islets should be transplanted, 5 million cells (Hogrebe et al. 2020; Maxwell et al. 2020b; 
Velazco-Cruz et al. 2019a). Regardless, the data presented here show similar in vivo functional 
potential between cryopreserved and control SC-islets.  
There is an immediate need for a model system of human primary islets. Human stem cell 
derived islets are a promising model system having already been used to model diabetes disease 
and in the development of novel cell replacement strategies. The 30+ day technically challenging 
SC-islet differentiation time along with their post mitotic non-proliferative nature, and dynamic 
in vitro stability (Velazco-Cruz et al. 2019a) makes biobanking of these cells a priority. 
Biobanking of SC-islets will allow for storage of large batch differentiations to increase 
uniformity and provide an on-demand supply of SC-islets, simplifying logistics of shipping and 
collaboration. Biobanked SC-islets can be characterized for safety, function, and composition to 
better inform experimental and therapeutic applications.  
This study showcases an SC-islet cryopreservation strategy to facilitate biobanking of SC-islets. 
We show that SC-islet cryopreservation does not significantly affect their functional or 
transcriptomic profiles relative to their non-cryopreserved counterparts. With the significance of 
SC-islets for diabetes cell therapies, future evaluation of direct transplantation of cryopreserved 
SC-islets into mice would be impactful to transplantation strategy. By avoiding the 2-day 
aggregation step, which requires suspension cell culture equipment and expertise, would 
facilitate transplantation logistics in the clinic. Cryopreservation of SC-islet clusters instead of 




4.5 Experimental Procedures 
Culture of hPSCs and differentiation to SC-islets 
hPSC culture and propagation was performed as described in (Hogrebe et al. 2020) for the 
adherent differentiation protocol. For the suspension differentiation protocol hPSC’s were 
cultured and propagated as in (Velazco-Cruz et al., 2019). The adherent differentiation protocol 
was used throughout this manuscript, unless otherwise stated. HUES8 (male) human embryonic 
stem cells (male) were used throughout this manuscript, unless stated that AN1.1 (female) 
human inuduced pluripotent stem cells where used. For adherent differentiations, hPSCs were 
differentiated to SC-islet as described in (Hogrebe et al. 2020). On Stage 6 Day 7 SC-islets were 
cryopreserved. For suspension differentiations, hPSC’s were differentiated to SC-islets as 
described in (Velazco-Cruz et al. 2019a). On Stage 6 Day 1 SC-islets were cryopreserved.  
Cryopreservation of SC-islets 
SC-islets derived with the adherent differentiation protocol where single cell dispersed on Stage 
6 Day 7 using TryplE Express (Gibco; 12604-013). Dispersed cells were washed once with PBS 
and counted with the cell counter Vi-Cell XR (Beckman Coulter) and resuspended at a 
concentration of 5-10million cells/ mL in 4°C cGMP manufactured serum-free, protein-free, 
chemically defined with 10% DMSO, cryoprotectant Prime-XV FReezIS (Fujifilm; 99139). 1mL 
aliquots of cell solution in cryoprotectant were transferred to cryovials, incubated at 4°C for 10 
minutes, and placed in a Mr. Frosty (ThermoFisher; 5100-0001) and transferred to a -80°C 
freezer to achieve a cooling rate of -1°C/minute. After overnight freezing in the -80°C freezer, 
cryopreserved SC-islets were transferred to liquid nitrogen storage. Alternatively, to Mr. Frosty 




cryoprotectant solution were placed in a Via Freeze (Asymptote) controlled rate freezer 
programed to incubate the cells at 4°C  for 10 minutes followed by a cooling rate of -1°C/minute 
until cell solution reaches -100°C, upon which cryopreserved SC-islets were transferred to liquid 
nitrogen storage. For SC-islets generated with the suspension differentiation protocol, Stage 6 
Day 1 SC-islet clusters were dispersed in TryplE Express. SC-islet clusters were incubated for 15 
minutes in TryplE Express within a 37°C water bath. Upon single cell dispersion clusters were 
washed with PBS and cryopreserved similarly to adherent derived SC-islets. Thawing of 
cryopreserved SC-islets was performed by removing cryovials from liquid nitrogen and thawing 
for 1 minute in a 37°C water bath. Cryovial was removed from water bath and washed with Stage 
6 media. 5-10 million cells were seeded into a well of 6 well plate to a final volume of 5 mL in 
Stage 6 media with 0.01 mg/mL of DNASE1. The 6-well plate was transferred into a tissue 
culture incubator on an orbital shaker set at 100RPM. 48 hours after thaw, aggregated SC-islet 
clusters undergo a media change to stage 6 media without DNASE1. Media changes occur every 
48 hours until assessed. Functional assessment is performed between 7-14 days post 
aggregation/thaw. 
Glucose Stimulated Insulin Secretion 
Assay was performed similarly to (Velazco-Cruz et al., 2019; Velazco-Cruz, Goedegebuure, & 
Millman, 2020; Velazco-Cruz, Goedegebuure, Maxwell, et al., 2020). ~30 SC-islet clusters per 
replicate are washed with KRB buffer and places into 0.4um mesh transwells (Millicell; 
PICMO1250) with basal KRB (2mM Glucose). Clusters are normalize to new conditions for 1 
hour  within a 37C 5%CO2 incubator. Following the 1 hour normalization, the cells are 




within a 37°C 5%CO2 incubator. Following the 1-hour basal incubation cells are transferred into 
stimulatory KRB (20mM glucose with or without additional secretagogues). Insulin elisa’s 
(ALPCO; 80-INSHU-E01.1) are used to measure end-point secreted insulin in basal and 
stimulatory conditions. Final secretagogue concentrations used:10 nM Extendin-4 
(MilliporeSigma; E7144), 100 μM IBMX (MilliporeSigma; I5879), 300 mM Tolbutamide 
(MilliporeSigma; T0891), or 30 mM KCL (ThermoFisher). 
Flow Cytometry 
Assay was performed as in (Velazco-Cruz et al. 2019a). SC-islet clusters were single-cell 
dispersed, fixed with 4% paraformaldehyde for 30 minutes at 4°C, and blocked with staining 
buffer (0.1% Trition X-100 (Acros Organics; 327371000), 5% donkey serum (Jackson 
Immunoresearch; 017-000-121), in PBS. Upon blocking, samples are incubated in primary 
antibodies overnight at 4°C followed by ta two hours secondary antibody incubation at 4°C. 
Stained cells were FACS analyzed on a Fortessa X020 (BD Biosciences). FlowJo was used for 
quantifications.  
Real-Time PCR 
Quantification of gene expression was performed as in (Velazco-Cruz et al. 2019a). RNA is 
extracted, cDNA is generated with reverse transcriptase reactions, and PowerUP SYBR Green 
(Applied Biosystems; A25741) was used to run real-time PCR reaction on a StepOnePlus 
(Applied Biosystems). TBP expression was used for normalization and quantified using 
△△Ct methodology. 




Assay was performed as in (Velazco-Cruz et al. 2019a). OCR and ECAR were measured with a  
Seahorse XFe24 flux analyzer (Agilent). 200,000 cells were seeded per well and incubated 
overnight in Stage 6 media. After overnight incubation assay was ran with RMPI-1640 (20mM 
Glucose) followed d by sequential treatment with 3 μM oligomycin (Calbiochem; 1404-19-9), 
0.25 μM carbonyl cyande-4-(trifluoromethoxy) phenylhydra-zone (FCCP) (Sigma; 270-86-5), 
and 1 μM rotenone (Calbiochem; 83-79-4) and 2 μM antimycin A (Sigma; 1397-94-0). 
Insulin and Proinsulin Content 
The assay was performed as in (Velazco-Cruz et al. 2019a). ~40 SC-islet clusters per replicate 
were placed in acid-ethanol (1.5% HCl and 70% ethanol). The cell solution was stored at −20°C 
for 24 hours. After 24 hours the cell solution was vortexed and again stored at −20°C for an 
additional 24 hours. After the 24 hours cell solution was vortexed and centrifuged at 2100 G for 
15 min. The supernatant was neutralized with an equal volume of 1 M TRIS (pH 7.5). Total 
Insulin and pro-insulin were quantified using Human Insulin ELISA and Proinsulin ELISA 
(Mercodia; 10-1118-01). Cell counts were used for normalization.  
Animal Transplantations 
Assay was performed similarly to (Hogrebe et al. 2020; Velazco-Cruz et al. 2019a). In vivo 
studies were carried out in accordance to the Washington University Institutional Animal Care 
and Use Committee regulations (protocol 20180203). 7-week-old male immunodeficient mice 
(NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) were purchased from Jackson Laboratories. Mice were 
transplanted with batch matched aggregate control or cryopreserved SC-islet clusters (~2 million 
cells per mouse) into the kidney capsule. After 4 weeks from transplantation mice were rendered 




plasma c-peptide were measured. In vivo GSIS was performed by fasting the mice overnight 
followed by an injection of 2g/kg of glucose solution in 0.9% saline, plasma c-peptide was 
measured prior to injection and 1-hour after injection. Glucose tolerance test were performed by 
fasting the mice overnight followed by an injection of 2g/kg of glucose solution in 0.9% saline. 
Blood glucose was measured prior to injection and every 30 minutes post injection for 2.5 hours. 
Human c-peptide was measured using a human c-peptide elisa (Mercodia; 10-1141-01). Blood 
glucose was measured using a glucometer (upper limit: 600mg/dl) 
Single-cell RNA Sequencing 
Single Cell RNA sequencing samples were prepared using batch-matched aggregate control and 
cryopreserved SC-islets. SC-Islet samples were dispersed into single cell suspension and each 
condition stained with hashing antibodies (Total SeqA, Biolegend) for multiplexing prior to 
submission. Library preparation was performed using Chromium Single Cell 3' Reagent Kits and 
analyzed with cellranger-6.0.0 by McDonnell Genome Institute at Washington University in St. 
Louis. Single Cell RNA Sequencing data analysis was performed using Seurat v4.0. We 











(A) Schematic of SC-islet cryopreservation strategy. 
(B) Immunostaining of sectioned cryopreserved SC-islets stained for NKX6-1, C-peptide (CP), 
chromogranin a (CHGA), or with the nuclei marker DAPI. Scale bar, 50 μm. 
(C) Representative bright field images of aggregated control, cryopreserved (Mr. Frosty), 
cryopreserved (controlled rate freezer) SC-islet clusters. Top row shows clusters 1-day after 
aggregation/thaw and the bottom row shows clusters 3-days after aggregation/thaw. Scale bar, 
150 μm. 
(D) % Viable cell recovery of aggregated control, cryopreserved (Mr. Frosty), cryopreserved 
(controlled rate freezer) SC-islet clusters, assessed 7 days post aggregation/thaw. N=4. 
(E) Representative flow cytometry dot plots of aggregated control, cryopreserved (Mr. Frosty), 
cryopreserved (controlled rate freezer) SC-islet clusters, assessed 7 days post aggregation/thaw.  
(F) Flow cytometry quantification of aggregated control, cryopreserved (Mr. Frosty), 
cryopreserved (controlled rate freezer) SC-islet clusters stained for C-peptide, NKX6.1, and 
chromogranin a (CHGA). Assessed 7 days post aggregation/thaw. n=4. 
(G) Static glucose-stimulated insulin secretion of aggregated control, cryopreserved (Mr. Frosty), 
cryopreserved (controlled rate freezer) SC-islet clusters. Assessed 7 days post aggregation/thaw. 
n=6. 
(H) Stimulation index bar graph of (G). n=6. 
∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001 by unpaired two-tailed t test relative to 








Figure 4.2. Functional Characterization of Cryopreserved SC-islets 
 
(A) Total insulin content of aggregated control and cryopreserved SC-islets. Assessed 7 days 
after aggregation/thaw. n=5. 
(B) Proinsulin/ Insulin content ratio of aggregated control and cryopreserved SC-islets. Assessed 




(C) OCR measurements for aggregated control and cryopreserved SC-islets measured under 
basal conditions and sequential Oligomycin (OM), Carbonyl cyanide4 
(trifluoromethoxy)phenylhydrazone (FCCP), and Antimycin A with rotenone (AA/R) treatments. 
n=10 for aggregated control and n=9 for cryopreserved SC-islets. Assessed 7 days after 
aggregation/thaw 
(D) OCR/ECAR ratio for (C) data. n=10 for aggregated control and n=9 for cryopreserved SC-
islets. 
(E) Secretagogue stimulated insulin secretion for aggregated control and cryopreserved SC-islets 
with 20mM glucose or 2mM glucose with IBMX, extendin-4, tolbutamide, or KCL.  Assessed 7 
days after aggregation/thaw. n=4. 
(F) Stimulation index for (E).  
(G) Caspase/Viability for aggregated control and cryopreserved SC-islets treated with a cytokine 
mix. (n=4). 
(H) Caspase/Viability for aggregated control and cryopreserved SC-islets treated with 10 μM 
thapsigargin. (n=3). 
∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001 by unpaired two-tailed t test relative to 










(A) Uniform manifold approximation and projection (UMAP) from unsupervised clustering of 
aggregated control and cryopreserved SC-islet scRNA-seq data.  
(B) Individual UMAPs for aggregated control and cryopreserved SC-islets showing expression 
of insulin (INS), glucagon (GCG), somatostatin (SST), and tryptophan hydroxylase 1(TPH1). 
(C) Population ratios for aggregated control and cryopreserved SC-islets. Derived from (A). 
(D) Volcano plot of the top 1000 differentially expressed markers within the β cell population 
between aggregated control and cryopreserved SC-islets.  
(E) Heat map of the top 1000 differentially expressed markers within the β cell population 
between aggregated control and cryopreserved SC-islets.  
(F) Violin plots of individual gene expression between aggregated control and cryopreserved 












Figure 4.4. SC-islet Transplantation into Mice.  
(A) Schematic of aggregated control and cryopreserved SC-islet transplantation.  
(B) Random blood glucose of STZ treated mice transplanted with aggregated control, 
cryopreserved, or no SC-islets. n=4. 
(C) Random human c-peptide of STZ treated mice transplanted with aggregated control, 
cryopreserved, or no SC-islets. n=4. 
(D) In vivo GSIS plasma human c-peptide in STZ treated and transplanted aggregation control or 
cryopreserved SC-islet mice. n=4. 
(E) Stimulation index of (D). 
(F) Glucose tolerance test of STZ treated and transplanted aggregation control. cryopreserved, or 




∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001 by unpaired two-tailed. Error bars represent 
s.e.m. 
 













Figure S4.1. Flow Cytometry and rt-PCR of Cryopreserved SC0islets 
 
(A) Representative flow cytometry dot plots of aggregated control and cryopreserved SC-islets. 
assessed 7 days post aggregation/thaw.  
(B) Representative flow cytometry dot plots of aggregated control and cryopreserved SC-islets 
clusters stained for c-peptide (CP), glucagon (GCG) and somatostatin (SST). Assessed 7 days 
post aggregation/thaw. n=3. 
(C) Real-time PCR assessed gene expression of cryopreserved SC-islets relative to their 
aggregated controls. n=4.  
(D) GSIS of cryopreserved AN1.1 iPSC derived SC-islets stored in liquid nitrogen for 48 hours, 
2 weeks, 2 months and 1 year. n=4.  
(E) % viable cell recovery of cryopreserved AN1.1 derived SC-islets stored in liquid nitrogen for 
48 hours, 2 weeks, 2 months and 1 year. n=4.  
(F) % viable cell recovery of aggregated control and cryopreserved SC-islets generated with the 
Velazco-Cruz et al. 2019 suspension differentiation protocol. n=4. 
(G) GSIS of aggregated control and cryopreserved SC-islets generated with the Velazco-Cruz et 
al. 2019 suspension differentiation protocol. n=4. 
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I write this section to condense my thesis path, findings, impact and future directions.  At the 
start of my thesis, the field had recently published two critical articles describing the in vitro 
generation of human pluripotent stem cell-derived  (SC-) cells (Millman et al. 2016; Pagliuca 
et al. 2014; Rezania et al. 2014). These early SC- cells were glucose responsive and capable of 
regulating blood glucose when transplanted into diabetic mice. SC- cells represent a significant 
advance towards solving the scarcity problem of human  cells for research and cell replacement 
therapy. Human  cells are post-mitotic, meaning they don’t replicate and rapidly loose identity 
during in vitro culture limiting biological studies. Transplantation of cadaveric islets into diabetic 
patients has been shown to successfully regulate blood glucose without the need for exogenous 
insulin, however the scarcity of cadaveric islets limits widespread application of diabetes cell 
replacement therapies(Farney, Sutherland, and Opara 2016). SC- cells can be generated in 
indefinite amounts potentially solving the scarcity issue. However, early SC- differentiation 
protocols show low function with high batch-to-batch variability. My thesis goal is to advance 
SC- cell technology by investigating and improving their functional maturity as well as 
developing supporting tools and methodologies for their application.  
 
In chapter 2, my work in (Velazco-Cruz et al. 2019a) was driven by the goal of improving SC- 
cell functional maturity. In pursuance of this goal, I generate a novel differentiation protocol 




signaling in the last stage of the differentiation protocol. I used the (Pagliuca et al. 2014) 
differentiation protocol as basis for developing the new differentiation protocol, ultimately 
making over 25 changes to the media compositions. Of note, stage three was reduced to 3 days 
preventing immature induction of endocrine cells, Rho kinase inhibitor Y27632 was added to 
stage three and four improving cell survival, and Activin A was introduced to stage four 
improving NKX6.1 induction. Cluster resizing was done to reduce cluster size and facilitate 
oxygen and nutrient diffusion. On average, cluster re-aggregation reduced cluster diameter from 
364 μm to 172 μm. Unexpectedly, we observed endocrine enrichment occurring during cluster 
aggregation due to lack of clustering capacity from non-endocrine cells. Most significantly 
permittance of TGF signaling most significantly drove the functional maturation of SC- cells, 
resulting in 9 times more insulin secretion than the starting Pagliuca protocol. Along with the 
improved insulin secretion, the new differentiation protocol yielded SC- cells capable of 
dynamic function, presenting a clear first-phase, stable second-phase, and return to basal 
secretion upon return to non-stimulatory glucose levels. Dynamic insulin secretion is the gold 
standard for assessing in vitro functional maturity and previously missing in SC- cells. Of 
particular intrigue, (Velazco-Cruz et al. 2019a) shows the TGF inhibition is necessary for the 
specification of the  cells fate and its subsequent permittance is necessary for their functional 
maturation. Previous differentiation protocols failed to decouple TGF’s role regarding SC- 
cell specification and functional maturation. The cellular aggregation and TGF permittance 
results from this paper have been well received in the field, having been independently 
reproduced by several groups (Liu et al. 2021; Nair et al. 2019; Veres et al. 2019). Important 




observed functional maturation and if TGF ligand treatment can improve SC- cell functional 
maturation.  
In Chapter 3, my (Velazco-Cruz et al. 2020) manuscript investigates transcription factors SIX2’s 
role in SC- cell differentiation and maturation. This article started as a follow up to (Velazco-
Cruz et al. 2019a), in which we identified permittance of TGF signaling is necessary for SC- 
cell functional maturation. I performed bulk RNA sequencing on TGF permitted vs TGF 
inhibited SC- cells and observed that SIX2 was highly enriched in the functionally mature 
TGF permitted SC- cells. A literature search revealed that SIX2 is restricted to the  cell 
population, it’s enriched in adult vs fetal and juvenile islets, its expression is human specific and 
GWAS studies associate it with diabetes (Arda et al. 2016; Spracklen et al. 2018; Xin et al. 
2016). I reveal SIX2 is not expressed until stage 6 of differentiation and its expression correlates 
with the functional maturation of SC- cells. Knockdown and knockout of SIX2 did not affect 
SC- cell fate specification, however it did inhibit their functional maturation. Significantly, 
SIX2 was observed to be expressed in only 25% of the c-peptide+ population. With the necessity 
of SIX2 for SC- cell functional maturation it calls into question whether the 75% of SIX2 
negative SC- cells contribute to the measured function. Additionally, one can postulate using 
SIX2 as a marker for further improving SC- cell differentiations.  Overexpression of SIX2 
should be examined to assess rescue potential of SIX2 KO’s. SIX2 over expression may also 
further improve functional potential of the cells. Generating a SIX2 fluorescent reporter hPSC 
line can facilitate identification of compound which modulate its function.  
In Chapter 4 of this thesis, I show an SC-islet cryopreservation strategy and investigate its effects 




cryopreservation of SC-islet clusters shows poor cell recovery due to poor penetration of 
cryoprotectant into cluster. Additionally, cryopreservation of single cell dispersed islet cells 
allows for endocrine enrichment by aggregation upon thaw. We use a chemically defined, 
protein free, 10% DMSO containing cGMP manufactured cryoprotectant solution for 
cryopreservation of the SC-islets. The cryopreserved SC-islets can be stored in liquid nitrogen 
for up to a year without impact to function or viable cell recovery. A panel of functional assays 
were used to assess cryopreserved SC-islet biology relative to non-cryopreserved contros. Insulin 
content, metabolic respiration, and secretagogue response were comparable between conditions. 
Transcriptomic analysis by single-cell sequencing reveals similar profiles with no significant 
differences between  cell transcriptomes. A small enrichment of endocrine cells is observed 
using flow cytometry, rt-PCR, and single cell sequencing. This is likely do t more rigorous 
depletion of non-endocrine cells which have lower aggregation potential. This endocrine 
enrichment is statistically significant however small in magnitude and undetectable in functional 
assays. Overall, this chapter shows cryopreserved SC-islets have intact biology and no reason to 
avoid use of cryopreserved SC-islets over non-cryopreserved. An important step for the broader 
application of SC-islets towards diabetes research and development of cell therapies.   
To the readers of this thesis, I hope you find my work useful and that you apply it to your own 
research. Chapter 2 has already had significant impact in the SC- cell field with most current 
differentiation protocols permitting TGF signaling and including an aggregation step to drive 
endocrine enrichment. These two techniques were not used prior to my publication yet are now 
considered standard by the field. It is yet not understood how TGF drives the observed 
functional maturation and remains a promising field of study. The functional maturation of SC- 




This is significant because MAFA is a widely recognized marker of mature human  cells and 
necessary for mouse  cell function. It is possible that MAFB which is expressed in SC- cells is 
compensating for the lack of MAFA. Overexpression of MAFA using ORF’s or CRISPRa 
should be tested to investigate MAFA’s biological and functional impact in SC- cells. I 
hypothesized SC- cells are a good experimental model for the study MAFB and MAFA’s role 
in  cell biology and that overexpression of MAFA will drive functional maturation. Chapter 3, 
uses SC- cells to understand SIX2’s effects on islet differentiation and biology. Such studies 
would be difficult to perform without SC- cell technology since SIX2 is absent in animal 
models and primary cells have a limited experimental toolbox. Manipulation of SIX2, such as 
overexpression, may improve on the functional maturity of SC- cell differentiations. SIX2’s 
correlation with function may also be a good marker of functional maturity.  I encourage readers 
of Chapter 4, to replicate my cryopreservation strategy and improve upon it. Efficient 
cryopreservation of SC-islets is a necessary step for wide application of this technology. In the 
appendix I describe techniques for using a luciferase reporter to measure SC-islet function and a 
technique for co-culturing SC-islets with endothelial cells. I encourage the readers to use these 
technological platforms in their own research.  On a final note, I encourage those reading my 
thesis or building on my work to contact me for advice or further discussion of my work.  
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A Luciferase Reporter of Insulin Secretion in 




Insulin-producing β-like cells derived from human pluripotent stem cells (SC-β cells) are 
emerging as powerful diabetes research tools. Here, we apply a luminescent insulin secretion 
reporter assay (Burns et al. 2018) to monitor SC- cell function without the need for ELISA 
assays. In response to glucose and other islet secretagogues, luciferase is secreted in correlation 
to insulin. Use of the reporter construct does not affect cell identity or native insulin secretion. 
We perform a proof-of-concept 472 compound screen using our luciferase reporter construct to 
identify  cell secretagogues. We identify 40 secretagogues from the screen and perform 
validation experiments in SC- and cadaveric islets. Calyculin A is validated as a potent and 
novel  secretagogue. Application of this luciferase insulin secretion reporter will facilitate 
monitoring of  cell function without the need for generating stable cell lines. 
A.2 Introduction 
Chronic diabetes, or diabetes mellitus, is the result of death or dysfunction of insulin-producing  
cells within the islet of Langerhans. Lack of blood glucose regulation can cause a number of 
complications throughout the body, including cardiovascular disease, nephropathy, neuropathy, 
and retinopathy (Nathan DM, Genuth S, Lachin J 1993). Diabetes mellitus affects over 450 




with diabetes have few treatment options: many rely on insulin injections, which are short-term 
and not precisely dosed for the individual. Another treatment is transplantation of cadaveric 
pancreatic islets, but these are limited in supply and transplantation requires immunosuppressants 
(Farney, Sutherland, and Opara 2016; McCall and Shapiro 2012). In response to this medical 
need, researchers have identified cell replacement therapy as a potential treatment using human 
pluripotent stem cells (hPSCs) differentiated into stem cell-derived  (SC-) cells (Millman and 
Pagliuca 2017a). Current SC- cells produce and dynamically secrete insulin in response to 
glucose restoring normal glycemia when transplanted into diabetic mice (Velazco-Cruz et al. 
2019a). However, they fail to match the insulin secretion of primary  cells.  
Constant efforts towards maturing SC- cells to resemble endogenous  cell biology and 
function are underway (Velazco-Cruz, Goedegebuure, and Millman 2020). Functionally mature 
SC- cells have the potential to act as surrogates to human primary  cells. Primary  cells are 
obtained from cadaveric donors and lose identity during in vitro culture making them extremely 
scarce for large scale biological and clinical application.  SC- cell functional maturity is directly 
assessed by measuring insulin secretion in response to glucose and other secretagogues using 
insulin ELISA assays. Elisa assays are accurate, however expensive and labor intensive limiting 
their applicability to compound screening libraries. Here we apply a luciferase insulin secretion 
reporter (LISR) assay to monitor function of SC- cells (Burns et al. 2018). Luciferase detection 
of insulin secretion avoids the expense and multiple liquid handling steps of ELISA or FRET 
assays, facilitating compound screens and lowering cost. Assessing function by luciferase 
detection cost < $0.01 per sample compared to insulin ELISA or Forster resonance energy 




(Burns et al. 2018) LISR construct in SC- cells. We measure correlation between luciferase and 
insulin in human embryonic (hESC) and induced pluripotent stem cells (hiPSC) in response to 
glucose and other secretagogues. We assess the reporter effects on SC- identity and endogenous 
insulin secretion as well as conduct a proof-of-concept 472 compound screen. 
A.3 Results 
The LISR construct is a lentiviral delivered transgene in which Gaussia luciferase replaces the 
C-peptide portion of the mouse proinsulin gene (Figure A1.A). We transduce the LISR reporter 
construct into differentiated SC- cells and correlate insulin secretion using insulin ELISA 
assays and correlate to secreted luciferase. The insulin ELISA does not cross-react with mouse 
insulin allowing one to specifically measure endogenous insulin secretion and not that translated 
from the mouse insulin gene. Insulin and luciferase secretion was measured in response to non-
stimulatory and stimulatory glucose levels (2, 5.6, 11.1, and 20mM), showing strong correlation 
with an r-squared value of 0.87 (p-value <0.0001) (Figure A1.B). Secretion of luciferase was 
assessed with multiple secretagogues, including 20mM glucose, tolbutamide, IBMX, extendin-4, 
and KCL. Insulin and luciferase secretion significantly correlated under tested secretagogues 
with a combined r-squared value of 0.80 (p-value <0.0001) (Figure A1.C). Dynamic function of 
LISR transduced SC- was assessed. Luciferase detection showed a clear first phase, stable 
second phase, return to basal, and KCl response correlating to insulin secretion with an r-squared 
value of 0.83 (p-value <0.0001) (Figure A1.D). Together (Figure A1.B-D) show luciferase is co-
secreted with insulin in degree and kinetics. Additionally, we show that luciferase secretion can 




with an r-squared value of 0.93 (p-value <0.0001) (Figure A1.E). Monitoring function of single-
SC- cell clusters with luciferase facilitates variance studies and increased sample capacity.  
Having established correlation of luciferase and insulin secretion, we assessed whether LISR 
expression impacted SC- cell fate or endogenous insulin secretion. Immunocytochemistry of 
control or LISR transduced SC- cells showed similar staining of C-peptide and NKX6.1 (Figure 
A2.A). Flow cytometry of C-peptide (CP), NKX6.1, and chromogranin A (CHGA) showed no 
significant difference in populations between control and LISR transduced SC- cells (Figure 
A2.B,C).  LISR effect on endogenous insulin secretion was assessed using glucose stimulated 
insulin secretion assays, in which sequential secreted insulin is measured under 2mM and 20mM 
hour long treatments. No significant difference in human insulin secretion was observed between 
control and LISR SC- cells (Figure A2.D). Additionally, the LISR was tested on hiPSC cell 
AN1.1 (female) derived SC- cells. Luciferase and insulin secreted in correlation with an r-
squared value of 0.92 (p-value <0.0001) (Figure A2.E).Unless otherwise stated all assays are 
performed on hESC HUES8 (male) derived SC- cells. Figure A2 shows LISR transduction does 
not affect SC- fate or endogenous secretion. 
In conjunction with Washington University in St. Louis High Throughput Screening Center we 
perform a pilot compound screen using LISR treated SC- cells and luciferase as a readout. We 
establish a semi-automated assay in which we single cell disperse SC- cells, plate them onto 
wells of 96-well plates, and perform a 472-compound screen using the ICCB Known Bioactives 
Library to identify  cell secretagogues (Figure A3). Figure A3.A shows a schematic of the 
compound screen.  From the screen we identify 40 compounds, both known and novel, which 




deviations or robust z-scores away from basal insulin secretion levels (Figure A3.B). The 
compound was ran using two replicates with an r-squared value of 0.51 and hits were called 
when both replicates met our significance cut off values (Figure A3.C). The top 30 hits are listed 
in Table A1. Future screens should increase replicate count to reduce variance and improve Z-
score. We validated a subset of the top hits in SC- and primary  cells (Figure A4). All tested 
compounds improved insulin secretion basal DMSO control in SC- cells (Figure A4.A). We 
then validated a subset of compounds on human cadaveric islet clusters (Figure A4.B).  Only 
PMA, Calyculin A and Ouabain had notable secretagogue capabilities. Possible reason for failure 
of other secretagogues not tested are likely due to the difference in biology between SC- cells 
and primary cadaveric islets or a lack of penetration of compounds into islet clusters. Compound 
screen and validation in SC- cells was done on single cell disperse and adhered cells, unlike 
cadaveric islets which were culture as non-adhered islet clusters.  PMA is a PKC activator and 
Oabain is a plant toxin acting as a sodium potassium pump inhibitor, both are known  cell 
secretagogues.  To our knowledge, phosphatase Calyculin A, is a novel  cell secretagogue 
(Figure A3.C). This screen was a proof-of-concept screen showing the synergies of SC- cells 
and the LISR system to facilitate  functional monitoring and large compound screens.  
A.4 Discussion 
 
Here we validate (Burns et al. 2018) LISR assay to monitor function of SC- cells.  Using LISR, 
luciferase is secreted in correlation to insulin under glucose and other secretagogues. Dynamic 
GSIS showed similar luciferase and insulin secretion kinetics. Additionally, we show the 




cluster function allows one to resolve endogenous functional variability of SC- cell clusters as 
well as increase sample size. Immunocytochemistry and flow cytometry analysis showed LISR 
transduction of SC- cells does not affect their endocrine and  cell marker expression. 
Furthermore, endogenous insulin secretion was not affected by LISR expression indicating 
differences in detected secretion are biologically relevant.  
As a proof-of-concept and in conjunction with the Washington University in St. Louis High 
Throughput Screening Center we perform a 472-compound screen, using the ICCB Known 
Bioactives library and the LISR assay. We identify 40 positive hits from the compound screens. 
Several of the hits were known secretagogues, such as PMA or forskolin, and many we classify 
as novel secretagogues. We validate a subset of hits from the screen using insulin ELISA in both 
SC- cells and cadaveric human islets. On average, all tested compounds improved stimulation 
index over basal levels. Validation in cadaveric islets clusters showed meaningful stimulation 
with PMA, Calcyculin A, and Ouabain treatment. Concentration curves should be performed on 
non-stimulatory compounds to address cluster penetration issues not present in the compound 
screen or SC- cell validation.  Of the hits, PMA a PKC activator and Ouabain a sodium pump 
inhibitor have known secretagogue capabilities. Calyculin A, a phosphatase inhibitor, is to our 
knowledge a novel  cell secretagogue. The secretory potential of Calyculin A is significant with 
a stimulation index of 8.29. Future work to evaluate Calyculin A’s pharmacological and 
toxicological impact on  cell biology should be evaluated.  
In summary, we establish a luciferase readout to monitor SC- cell function. To our knowledge, 
this is the first application of such functional monitoring of SC- cells. SC- fluorescent or 




et al. 2021) or gene expression ((Gupta et al. 2018; Liu et al. 2014; Nair et al. 2019), however not 
for direct functional monitoring of SC- cells. By using a lentiviral delivered system, we avoid 
the need of generating a stable cell line, saving time and facilitating use of this technology under 
different genetic backgrounds. Combining LISR and SC- cell technology for pharmacological 
assessment and screening provides a unique and powerful method to investigate and discover 
new  cell drugs.   
A.5 Experimental Procedures 
 
Stem cell culture and differentiation 
 
Human pluripotent stem cell culture was performed as described in (Hogrebe et al., 2020). This 
work was performed with the approval of the Washington University School of Medicine 
Embryonic Stem Cell Research Oversight Committee (ESCRO). Differentiations were 
performed using HUES8 hESC and AN1.1 hiPSC lines. If cell line is not specified, data was 
obtained using HUES8 hESC’s. Data obtained with AN1.1 hIPSC’s is specified in text and 
figure legends.   
Immunostaining 
Immunostaining was performed as in (Velazco-Cruz et al. 2020). Transduced SC- cell clusters 
were single-cell dispersed with trypLE, plated overnight, and fixed with 4% paraformaldehyde 
(Electron Microscopy Science; 15714) for 30 min at RT. Samples were treated for 30 min with 
immunostaining solution followed by overnight 4°C  incubation with primary antibodies in 
immunostaining solution. After primary staining, cells were incubated for two hours at 4°C with 




confocal microscope. Immunostaining solution was made using 5% donkey serum (Jackson 
Immunoresearch; 017-000-121) and 0.1% Triton X-100 (Acros Organics; 327371000) in PBS. 
Flowcytometry 
Flowcytometry was performed similarly to (Hogrebe et al. 2021). SC-β cells were single cell 
disperse using TrypLE, fixed with 4% PFA for 30 minutes at 4°C, blocked with immunostaining 
solutions for 30 minutes at 4°C, stained with primary antibodies overnight at 4°C, washed, 
incubated with secondary antibodies, and analyzed on an X-20 (BD Biosciences) FACS 
analyzer. FlowJo was used for data analysis.  
Glucose stimulated insulin/luciferase secretion 
GSIS was performed as described in (Hogrebe et al. 2021). Stage 6 day 14 SC-β cell clusters 
were washed with KrB, placed into cell inserts (MilliporeSigma; PIXP01250), equilibrated in 
2mM glucose KrB for 1 hour, transferred to a fresh 2mM  glucose KrB well for an additional 
hour, transferred to a 20mM glucose for an additional hour. Cultured KrB for the 2mM and 
20mM glucose treatment was collected for analysis. Normalization was done by measuring cell 
count. Insulin was measured using human insulin ELISA (ALPCO, cat. no. 80-INSHU-E01.1). 
Secreted luciferase was measured using GLuc GLOW assay (Nanolight Technology; 320) and 
read on a standard plate reader (BioTeK). For assays using cadaveric human islets, they were 
obtained from PRODO labs.  
Lentiviral production and transduction 
LISR lentivirus production was done using Proinsulin-NanoLuc plasmid (Adgene Plasmid 
#62057) (Burns et al. 2016). Lentiviiral particles were generated as in (Velazco-Cruz et al. 
2020).  Lenti-X 293T cells (Takara; 632180) cultured in DMEM (MilliporeSigma; D6429) with 




transfected with 6 μg of LISR plasmid, 4.5 μg of psPAX2 (Addgene; 12260), and 1.5 μg 
pMD2.G (Addgene; 12259) packaging plasmids in 600 μL of Opti-MEM (Life 
Technologies;31985–070) and 48 μL of Polyethylenimine ‘Max’ MW 40,000 Da (Polysciences; 
24765–2). 16 hours post transfection, transfected Lenti-X 293T cells were fed with fresh media. 
LISR viral particles were collected 96 hours post transfection and concentrated using Lenti-X 
concentrator (Takara; 631232). Lenti-X qRT-PCR Titration Kit (Takara; 631235) was used for 
titration. Stage 6 Day 7 cells were transduced with LISR lentiviral particles at an MOI of 5. 
Media was switched 16 hours post transduction. psPAX2 and pMD2.G were a gift from Didier 
Trono. 
High-throughput Compound Screen 
Compound screen was conducted in conjunction with Washington University in St. Louis High-
Throughput Screening Core. Screen was ran in duplicate (n=2). Stage 6 Day 14 SC-β cell 
clusters were single-cell dispersed in TrypLE and 20,000 cells/well were plated onto black with 
clear bottom 96-well plates and allowed to attach overnight in a 5% CO2 37°C tissue culture 
incubator. On the day of assay, ICCB Known Bioactives 472-comoound library was pre-
dispensed into dilution plates using a Humminbird liquid handler. Compund concentration 
varied, with a constant final 0.1% DMSO between all conditions. Using microplate washer 
ELx405 CW, plated cells were washed twice with 2mM glucose KRB and equilibrated for 1 hour 
in 2mM glucose KRB inside a 37C 5%CO2 incubator. After equilibration treatment cell plates 
were washed twice with 2mM glucose KRB and resuspended in 2mM glucose KRB and 
compound library added using BiomekFX liquid handler. Cells were incubated for 1 hour at 37C 
5%CO2. After 1-hour incubation supernatant was transferred to a collection plate for analysis. 




using GLuc GLOW assay (Nanolight Technology; 320) and read on a multi-plate reader 
(BioTeK). Screen was ran in duplicate (n=2) and hits were called when both duplicates were 




Figure A.1. SC-islet luciferase reporter 
(A) Schematic of LSIR assay. 
(B) Luciferase and insulin secretion after one hour culture in 2mM, 5.6mM, 11.1mM, or 20mM 
glucose Krebb buffer. n=5 per treatment.  
(C) Luciferase secretion in response to multiple secretagogues. Secreted luciferase is correlated 





(D) Perfusion GSIS correlating luciferase and insulin secretion. n=4.  
(E) Sequential glucose and KCl GSIS correlating luciferase and insulin secretion. n=8.  
For C and E  ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001 by unpaired two-tailed t test 




Figure A.2. Luciferase reporter does not affect cellular composition or insulin secretion  
(A) Immunostaining of control and LISR transduced SC- cells.  




(C) Flow cytometry quantification of control and LISR transduced cells for indicated markers. 
n=7. 
(D) Glucose stimulated insulin secretion of control and LISR transduced SC- cells. n=5.  
(E) GSIS assay in AN1.1 hIPSC’s correlating luciferase and insulin secretion. n=6.  
For C and E  ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001 by unpaired two-tailed t test. Error 









Figure A.3. SC- cell compound screen with luciferase reporter 
(A) Compound screen schematic 
(B) Heatmap of compound screen showing luciferase foldchanges relative to control.    






Figure A.4.  Validation of compound screen hits  
(A) SC- cell validation of compound screen hits. n=4. 
(B) Human cadaveric islet validation of compound screen hits. n=4. 
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B.1 Abstract 
Differentiation of stem cells into functional replacement cells and tissues is a major goal of the 
regenerative medicine field. However, one limitation has been organization of differentiated cells 
into multi-cellular, three-dimensional assemblies. The islets of Langerhans contain many 
endocrine and non-endocrine cell types, such as insulin-producing β cells and endothelial cells. 
Despite the potential importance of endothelial cells to islet function, facilitating interactions 
between endothelial cells and islet endocrine cell types already differentiated from human 
embryonic stem cells has been difficult in vitro. We have developed a strategy of assembling 
human embryonic stem cell-derived islet cells with endothelial cells into three-dimensional 
aggregates on a hydrogel. The resulting islet organoids express β cell and other endocrine 
markers and are functional, capable of undergoing glucose-stimulated insulin secretion. This 
assembly was not observed on traditional tissue culture plastic and in aggregates generated in 
suspension culture, highlighting how physical culture conditions greatly influence the 




the islet tissue microenvironment on human embryonic stem cell-derived β cells and other islet 
endocrine cells to develop tissue engineered islets. 
B.2 Introduction 
In diabetes, insulin-producing β cells, which are located within islets of Langerhans in the 
pancreas, are dysfunctional or destroyed by high levels of metabolites, such as glucotoxicity or 
lipotoxicity, or by autoimmune attack. The rapid rise in diabetes prevalence has generated much 
attention towards the development of technologies to better study and treat this disease. 
However, there is no cure for diabetes, and current treatments are insufficient in controlling the 
disease for many patients. A small number of patients have been transplanted with cadaveric 
human islets, which contain β cells, and remained insulin independent for years (Bellin et al. 
2012). Unfortunately, this approach is limited because of the scarcity and variability of isolated 
human islets available for patients, whom often require islets from multiple donors to achieve 
normal blood sugar levels (McCall and Shapiro 2012). 
Several reports by us and others have detailed approaches for making insulin-producing β-like 
cells from human embryonic stem cells (hESCs) with the goal that these cells could be used for 
both cell replacement therapy and drug screening for diabetes (Ghazizadeh et al. 2017; Millman 
et al. 2016; Nair et al. 2019; Pagliuca et al. 2014; Rezania et al. 2014; Velazco-Cruz et al. 
2019b). These hESC-derived β (SC-β) cells are capable of undergoing glucose-stimulated insulin 
secretion and express markers found in β cells. While current methodologies produce final cell 
populations containing SC-β cells, the cellular composition is significantly different than islets 




visually resembling islets and having functional SC-β cells that are electrically coupled 
according to Ca2+ flux measurements (Pagliuca et al. 2014; Srivatsava et al. 2019), differ 
significantly from human islets. The differentiation process does produce cells expressing 
hormones indicative of other islet endocrine cell types, such as glucagon and somatostatin, but 
endothelial cells (ECs) are absent. The native islet microenvironment, which is influenced in part 
by ECs, is highly specialized in supporting islet architecture and function (Pagliuca and Melton 
2013). This three-dimensional islet environment facilitates β cell-β cell and β cell-EC 
interactions which altogether support β cell survival and insulin secretion. Specifically, ECs 
produce extracellular matrix (ECM) proteins to provide such interactions (Kragl and Lammert 
2010; Stendahl, Kaufman, and Stupp 2009). 
Modulating the microenvironment that SC-β cells experience to be more islet-like is 
technologically challenging with current approaches. In particular, facilitating interactions 
between ECs and already differentiated SC-β cells and other SC-islet endocrine cell types has 
been difficult in vitro, limiting study of the influence of ECs on SC-islet maturation and function. 
As SC-β cells are derived from the endoderm germ layer and endothelial cells from mesoderm, 
robust simultaneous differentiation of both cell types in the same culture is not possible. This is 
because current directed differentiation protocols specify only one germ layer. Approaches 
focused on assembly of multiple cell types during or after differentiation are therefore preferable. 
However, currently culture of aggregates containing SC-β cells in suspension is commonly 
performed on shaker plates or spinner flasks (Velazco-Cruz et al. 2019b), which requires 
expensive water-, heat-, and CO2-resistant equipment and expertise with hESC culture in 
reactors, or on air-liquid-interfaces (Rezania et al. 2014), which requires manual formation of 





Here we established a platform for the assembly of islet-like organoids with already 
differentiated SC-β cells and ECs. These parameters allow for SC-β cells to assemble and 
interact with ECs when cultured on Matrigel hydrogel slabs. The heterozygous cell assembles 
express markers found in islets and are capable of undergoing glucose-stimulated insulin 
secretion. In contrast, SC-β cells and ECs did not assemble when plated in two-dimensional 
culture on standard tissue culture plastic coated with dilute Matrigel or with aggregation in 
suspension culture. This platform facilitates the study of SC-β cell/EC interactions as well as 
tissue engineering of islet organoids to further improve SC-islet performance. 
B.3 Results 
B.3.1 Development of platform for SC-β cells and EC assembly 
We have previously published a protocol for the generation of SC-β cells from hESCs (Velazco-
Cruz et al. 2019b) (Fig. B.1A). This approach is done entirely in suspension culture with the cells 
grown as multicellular aggregates >100 µm for between 31 and 41 d (Fig. B.1B-C). Specific 
growth factors and molecules are given in different combinations as differentiation progresses to 
recapitulate pancreatic development. This protocol generates cellular aggregates containing 
populations of cells with varying degrees of staining for C-peptide, which produced by 
the INS gene and cleaved away from the mature insulin peptide during processing, as well as 




While this differentiation protocol produces SC-β cells, ECs are absent (Fig. B.1E), in contrast to 
what is seen in native islets (Olsson and Carlsson 2006). In order to develop a platform that 
enables study of SC-β cells and ECs, we first attempted to disperse the SC-β cell clusters our 
protocol normally generates, mix with a single-cell dispersion of ECs, and allow them to 
spontaneously reaggregate in a 6-well plate on an orbital shaker at 100 rpm, as we have used to 
previously reaggregated SC-β cell clusters (Velazco-Cruz et al. 2019b). The morphology of the 
resulting clusters was unaffected by the attempted inclusion of ECs (Fig. B.1F). To check for the 
incorporation of ECs, we dispersed and plated the reaggregated clusters, then stained for C-
peptide, to mark SC-β cells, and CD31, an endothelial cell marker (Fig. B.1G). We observed 
little to no CD31+ cells, indicating this approach did not enable ECs to be incorporated with the 
SC-β cell clusters. This is likely due to death of the ECs during aggregation, which was not 
prevented by the presence of SC-β cell and other Stage 6 cells. Overall, we observed that 
hydrogel-free suspension-based aggregation did not result in significant assembly of SC-β cells 
with ECs. 
B.3.2 Hydrogel platform enables SC-β cells and EC assembly 
After observing the difficulty of facilitating C-peptide+ and CD31+ cell physical association 
with our standard cluster-based protocol, we turned to using Matrigel, which is a protein mixture 
derived from mouse sarcoma cells that consists in part of basement membrane extracellular 
matrix proteins. This material was chosen because it is widely availability and easy to use, using 
temperature to induce gelation. In addition, we chose to use standard, non-growth factor reduced 
Matrigel in the hopes of promoting assembly. As hESCs are commonly cultured on tissue culture 




coating to promote attachment, we first attempted plating a single-cell dispersion of SC-β cells 
mixed with ECs on the bottom of a dilute Matrigel-coated tissue culture plate and assessed with 
immunostaining (Fig. B.2A). While we observed both C-peptide+ and CD31+ cells, these 
populations tended to segregate away from each other, with only 6 ± 1% of C-peptide+ cells 
touching a CD31+ cell (Fig. B.2B). Next, we created slabs of undiluted Matrigel hydrogels and 
dispensed a mixture of single-cell dispersed SC-β cells and ECs at varying ratios on top. We 
observed assembly of cells after 24 h (Fig. B.2C). Both 1:1 and 3:1 ratios of SC-β cell to EC 
produced three-dimensional structures resembling tubule networks, and higher ratios of ECs 
tended to produce more sheet-like morphologies. ECs are likely secreting pro-migratory factors 
that attract SC-β cells to the network, since SC-β cells without ECs, while producing small 
aggregates, appeared fairly uniformly scattered across the hydrogel. This is also interesting 
because this aggregation with ECs did not require the normal equipment used for SC-β cell 
culture and aggregation: Stirrer, shakers, and/or spinner flasks. 
We whole-mount immunostained the resulting islet organoids made with the 3:1 ratio of SC-β 
cells to ECs and confirmed that the assembled tubule network was formed by the CD31+ and C-
peptide+ cells (Fig. B.2D). Most (84 ± 4%) of C-peptide+ cells were incorporated into the 
aggregates (Fig. B.2E), which is a significant increase (p < 0.0001 by unpaired two-way t-test) 
compared to two-dimensional assembly (Fig. B.2B). Confocal image construction confirmed that 
most C-peptide+ cells were incorporated into the assembly (Fig. B.3). Taken together, these data 
demonstrate that three-dimensional assembly of already differentiated SC-β cells and ECs can be 




B.3.3 Characterization of islet organoids 
To characterize islet organoid assembly using our developed platform, we qualitatively assessed 
the viability of our constructs 24 and 96 h after assembly using a Live/Dead 
Viability/Cytotoxicity Kit, which fluorescently stains live cells green and dead cells, defined as 
membrane-permeable, red (Fig. B.4A). Minimal cell death was observed, which was mostly 
restricted to regions away from the cellular constructs. To quantify viability, we dispersed the 
organoids, stained with dithizone, a dye that stains β cells red, and trypan blue, a dye that stains 
dead (membrane permeable) cells blue, and quantified the fractions, comparing to stage 6 cells 
without ECs (Fig. B.4B-C). Greater than 80% of dithizone+ cells and dithizone-, which would 
largely consist of ECs, cells were viable at both 24 and 96 h from both organoids and Stage 6 
aggregates, demonstrating that the platform did not negatively affect viability. These data show 
that our assembly platform enables expression of EC and islet endocrine markers while 
maintaining viability. 
To evaluate the potential of this platform for islet organoid assembly for evaluating islet 
microenvironment parameters, we performed a glucose-stimulated insulin secretion assay of SC-
β cell/EC assemblies (Fig. B.5). The normal physiological function of pancreatic β cells in the 
body is to secrete insulin in response to high glucose stimulation. This in vitro assay involves 
treating cells first with low (2 mM) glucose for an hour, collecting the resulting supernatant, then 
subsequently treating cells with high (20 mM) glucose for an hour, collecting the resulting 
supernatant, and quantifying the amount of insulin released with ELISA. Testing three 
independent replicates of the islet organoid assembly revealed all three were robustly functional 




secretion increased by 3.9 ± 0.3x by high glucose stimulation. This function was comparable to 
our Stage 6 aggregates. These data show that the assembled islet organoids are glucose-
responsive and secrete insulin. 
Finally, we evaluated our SC-β cell/EC assemblies by expression of β cell genes (Fig. B.6A). 
Key genes associated with β cell identity, including insulin (INS), transcription factors (MAFB, 
PDX1, NKX6-1, NKX2-2, NEUROD1), and with function (CHGA, GCK) were all highly 
expressed in our assembled islet organoids compared to undifferentiated hESC controls and were 
overall comparable in expression with Stage 6 aggregates without ECs and human islets. CHGA 
and GCK were notable exceptions, with higher expression in islet organoids than human islets. 
Furthermore, we confirmed that the C-peptide+ cells co-expressed PDX1 and NKX6-1 and that 
other endocrine cells, indicated by being glucagon+, were present within the organoids (Fig. 
B.6B). These data show that SC-β cell assemblies made with our platform maintain expression 
of β cell and islet markers. 
B.4 Discussion 
The islets of Langerhans are complex, multicellular tissues that are responsible for maintaining 
glucose tolerance within humans through their ability to sense glucose and secrete hormones. 
Islets consist of β cells and other endocrine cell types along with ECs. Despite the potential 
importance of ECs to islet function, facilitating direct interactions between ECs and already 
differentiated and functional SC-β cells has been difficult in vitro. Here we developed a platform 
that enables the assembly of already differentiated SC-β cells and other endocrine cells with ECs. 




secretion, a key β cell functional feature, and expressed a panel of β cell genes that are associated 
with its identity and function. We encountered difficulties successfully assembling SC-β cells 
with ECs using other approaches, indicating that the conditions for this phenotype are limited. In 
particular, we observed that SC-β cells are capable of assembling with ECs when cultured on top 
of a slab of polymerized Matrigel but not on traditional tissue culture plastic coated with dilute 
Matrigel, highlighting how physical culture conditions can greatly influence the interaction 
between these two cell types. Importantly, this platform facilitates the study of potential 
improvements to SC-β cells and SC-islets maturation and function by studying and improving 
interactions with ECs. 
Current protocols produce SC-β cells that resemble their in vivo counterparts in many important 
parameters but are still different in other aspects. While SC-β cells are capable of undergoing 
glucose-stimulated insulin secretion and controlling blood sugar levels in mice, how glucose-
responsive the cells are and how much insulin the cells secrete is still lower than primary 
cadaveric human islets (Nair et al. 2019; Pagliuca et al. 2014; Rezania et al. 2014; Velazco-Cruz 
et al. 2019b; Veres et al. 2019). SC-β cells express many markers found in primary cadaveric 
human islets, but several genes associated with maturation continue to be under expressed, such 
as MAFA and UCN3 (Velazco-Cruz et al. 2019b; Veres et al. 2019). We hope our reported 
platform for assembling key islet components enables future studies to identify the parameters to 
make more mature SC-β cells in tissue engineered islets by utilizing ECs, as this was not pursued 
in this study. A practical feature of our platform is that it can be achieved without specialized 
reagents, equipment, or training, which will facilitate future studies and is in contrast with 




Approaches have been developed in order to generate SC-β cell-containing aggregates that better 
resemble native islets. Optimization of the timing and combinations of soluble small molecules 
and growth factors have led to increases in differentiation yield (Velazco-Cruz et al. 2019b). 
Resizing of clusters has led to increased function both in vitro and in vivo (Nair et al. 2019; 
Rezania et al. 2014; Song and Millman 2017; Velazco-Cruz et al. 2019b), in part by limiting 
hypoxia (Song and Millman 2017). Sorting based on a transgenic reporter (Nair et al. 2019) or 
surface marker (Rezania et al. 2014) has allowed further increases in the purity of SC-β cells to 
better define the cellular population present in aggregates. Combining 3D printing with fibrin 
gels has better enabled transplantation of resized SC-β cell clusters (Song and Millman 2017). 
Our current work presents a hydrogel platform that now allows for the physical interaction of 
ECs with already differentiated SC-β cells that can take advantage of current and future 
improvements in SC-β cell differentiation and maturation approaches, which will bring stem cell 
technology closer to clinical translation and increase our understanding of β cell biology and 
diabetes pathology. 
Prior studies that have investigated ECs combined them with pluripotent stem cells or pancreatic 
progenitors as they are differentiating to insulin-expressing cells, using the ECs as a 
differentiation factor, and observed benefits of the ECs in differentiation yield and insulin 
secretion (Candiello et al. 2018; Jaramillo et al. 2014; Talavera-Adame et al. 2016). However, a 
major difference in our study and development of the hydrogel platform compared to these prior 
EC studies is that we started with SC-β cells that we had already differentiated without using 
ECs using a chemical method (Velazco-Cruz et al. 2019b). In particular, we used our chemical 
differentiation factor approach that generates 73% C-peptide+ cells that secretes approximately 




controlling diabetes in mice (Velazco-Cruz et al. 2019b). In contrast, Candiello et al. reported a 
system of combining ECs with differentiating hESCs (Candiello et al. 2018) but only achieved 
insulin secretion per cell of 3–5 µIU of insulin per 105 cells, about 102 times lower than achieved 
with our new platform here containing ECs or with our reported chemical differentiation factor 
based-approach (Velazco-Cruz et al. 2019b). Our chemical differentiation factor based-approach 
possibly already provides the same or similar signaling that ECs provided in the prior 
studies (Candiello et al. 2018; Jaramillo et al. 2014; Talavera-Adame et al. 2016). Because of the 
high differentiation yields and function our SC-β cell chemical differentiation factor approach 
can already achieve, we were motivated to build our new cell assembly platform described here 
using these already differentiated and functional SC-β cells to enable development of improved 
SC-β cells and islets compared to both current EC-based and differentiation factor based-
approaches. 
While we did not find success with several approaches that we attempted, alternative 
methodologies could be developed to assemble ECs and SC-β cells. We recently used microwells 
to resize and enable embedding of SC-β cell aggregates into fibrin gels within a 3D-printed 
macroporous device before transplantation, but introduction of ECs was not studied (Song and 
Millman 2017). The specific factors promoting assembly was not identified in this study. 
However, we do demonstrate that the physical culture conditions were crucial to SC-β cell/EC 
interactions. Specifically, only culture on top of Matrigel hydrogel slab supported physical 
interaction between the two cell types but not on top of traditional tissue culture polystyrene with 
a thin coat of Matrigel. Additional study of the successes and failures of islet organoid assembly 
could yield additional insights, such as the studying the role of growth factors and particular 




laminin (Kleinman et al. 1982), laminin has been found to be beneficial for islets (Nikolova et al. 
2006), and laminin promotes vascular network formation in scaffolds (Stamati et al. 2014), 
further mechanistic studies into the role of laminin in the islet organoid assembly process is 
warranted. There are also likely alternative hydrogels or materials, including other basement 
membrane matrixes formulations, that would work in assembling islet organoids and reduce cost 
or non-biological materials (Youngblood et al. 2019). 
Our findings show that assembly of already differentiated SC-β cells with ECs will only occur 
under specific culture conditions. Specifically, suspension aggregation into clusters or assembly 
on tissue culture plastic coated with dilute Matrigel were unable to induce interactions between 
SC-β cells and ECs. However, we observed that dispersing and plating SC-β cells with ECs on 
top of Matrigel induced the physical interaction between the two cell types. These assembled 
islet organoids were able to undergo glucose-stimulated insulin secretion and expressed a panel 
of β cell and other endocrine markers. Our described approach provides a platform for the study 
of key microenvironmental components for the development of tissue engineered islet for 
diabetes cell replacement therapy and drug screening. 
B.5 Experimental Procedures 
Stem cell culture 
The HUES8 hESC line was generously provided by Dr. Douglas Melton (Harvard University) 
and has been previously published (Pagliuca et al. 2014; Velazco-Cruz et al. 2019b). These cells 
were cultured in an undifferentiated state in mTeSR1 (StemCell Technologies; 05850) in 100-




(Chemglass) set at 60 RPM in a humidified incubator set at 5% CO2 and 37 °C. Accutase 
(StemCell Technologies; 07920) was used to passage cells every 3 d. The Vi-Cell XR (Beckman 
Coulter) was used to quantify viable cell counts and 6 × 105 cells/mL in mTeSR1 + 10 μM 
Y27632 (Abcam; ab120129) were seeded back into the flasks. 
Differentiation of SC- β cells 
Differentiation was performed as developed and described by us in  (Velazco-Cruz et al. 2019b). 
Undifferentiated hESCs were seeded into 30-mL spinner flasks, cultured for 3 d in mTeSR1, and 
then cultured in the following conditions in order: 
Stage 1: 3 days in S1 basal media with 100 ng/ml Activin A (R&D Systems; 338-AC) and 3 μM 
CHIR99021 (Stemgent; 04–0004-10) for 1 day followed by S1 basal media with 100 ng/ml 
Activin A for 2 days. 
Stage 2: 3 days in S2 basal media with 50 ng/ml KGF (Peprotech; AF-100–19). 
Stage 3: 1 day in S3 basal media with 50 ng/ml KGF, 200 nM LDN193189 (Reprocell; 040074), 
500 nM PdBU (MilliporeSigma; 524390), 2 μM Retinoic Acid (MilliporeSigma; R2625), 
0.25 μM Sant1 (MilliporeSigma; S4572), and 10 µM Y27632. 
Stage 4: 5 days in S3 basal media with 5 ng/ml Activin A, 50 ng/ml KGF, 0.1 µM Retinoic Acid, 
0.25 µM SANT1, and 10 µM Y27632. 
Stage 5: 7 days in S5 basal media with 10 µM ALK5i II (Enzo Life Sciences; ALX-270-445-
M005), 20 ng/ml Betacellulin (R&D Systems; 261-CE-050), 0.1 µM Retinoic Acid, 0.25 µM 




this stage, clusters were reaggregated by dispersion with TrypLE Express (ThermoFisher; 
12604013) and replating in a 6-well plate on an Orbi-Shaker (Benchmark). 
Stage 6: 12–22 days in enhanced serum-free media (ESFM). 
The basal media formulations are as follows: 
S1 basal media: 500 mL MCDB 131 (Cellgro; 15–100-CV) plus 0.22 g glucose 
(MilliporeSigma; G7528), 1.23 g sodium bicarbonate (MilliporeSigma; S3817), 10 g bovine 
serum albumin (BSA) (Proliant; 68700), 10 µL ITS-X (Invitrogen; 51500056), 5 mL GlutaMAX 
(Invitrogen; 35050079), 22 mg vitamin C (MilliporeSigma; A4544), and 5 mL 
penicillin/streptomycin (P/S) solution (Cellgro; 30-002-CI). 
S2 basal media: 500 mL MCDB 131 plus 0.22 g glucose, 0.615 g sodium bicarbonate, 10 g BSA, 
10 µL ITS-X, 5 mL GlutaMAX, 22 mg vitamin C, and 5 mL P/S. 
S3 basal media: 500 mL MCDB 131 plus 0.22 g glucose, 0.615 g sodium bicarbonate, 10 g BSA, 
2.5 mL ITS-X, 5 mL GlutaMAX, 22 mg vitamin C, and 5 mL P/S. 
S5 media: 500 mL MCDB 131 plus 1.8 g glucose, 0.877 g sodium bicarbonate, 10 g BSA, 
2.5 mL ITS-X, 5 mL GlutaMAX, 22 mg vitamin C, 5 mL P/S, and 5 mg heparin 
(MilliporeSigma; A4544). 
ESFM: 500 mL MCDB 131 plus 0.23 g glucose, 10.5 g BSA, 5.2 mL GlutaMAX, 5.2 mL P/S, 
5 mg heparin, 5.2 mL MEM nonessential amino acids (Corning; 20–025-CI), 84 µg 
ZnSO4 (MilliporeSigma; 10883), 523 µL Trace Elements A (Corning; 25–021-CI), and 523 µL 





Images of cell clusters unstained or stained with 2.5 µg/mL dithizone (MilliporeSigma; 194832) 
were taken with an inverted light microscope (Leica DMi1). 
Immunohistochemistry 
Clusters were fixed with 4% paraformaldehyde (Electron Microscopy Science; 15714) overnight 
at 4 °C, embedded in Histogel (Thermo Scientific; hg-4000-012), and paraffin-embedded and 
sectioned by the Division of Comparative Medicine (DCM) Research Animal Diagnostic 
Laboratory Core at Washington University. Immunostaining was performed by paraffin removal 
with Histoclear (Thermo Scientific; C78-2-G), rehydration by treatment with increasing ratios of 
water to ethanol, antigens retrieved by treatment with 0.05 M EDTA (Ambion; AM9261) in a 
pressure cooker (Proteogenix; 2100 Retriever). Non-specific antibody binding was blocked with 
a 30-min treatment in staining buffer (5% donkey serum (Jackson Immunoresearch; 017-000-
121) and 0.1% Triton-X 100 (Acros Organics; 327371000) in PBS), followed by overnight 
staining with 1:300 dilutions of rat-anti-C-peptide (DSHB; GN-ID4-S) and mouse-anti-glucagon 
(ABCAM; ab82270) primary antibodies or only with buffer. Samples were stained with donkey 
secondary antibodies containing Alexa Fluor fluorophores (Invitrogen) for 2 h at 4 °C, and 
treated with DAPI in the mounting solution Fluoromount-G (SouthernBiotech; 0100-20). 
Imaging was performed on a Nikon A1Rsi confocal microscope. 
Whole-mount immunostaining 
Cells or cell assemblies were fixed within the well using 4% paraformaldehyde treatment 
overnight at 4 °C. Non-specific antibody binding was blocked with a 30-min treatment in 




100 (Acros Organics; 327371000) in PBS) followed by overnight staining with 1:300 dilutions 
of rat-anti-C-peptide (DSHB; GN-ID4-S), mouse-anti-CD31 (Dako; M082329-2), goat-anti-
PDX1 (R&D Systems; AF2419), and/or mouse-anti-NKX6-1 (University of Iowa, 
Developmental Hybridoma Bank; F55A12-supernatant) primary antibodies. Samples were 
stained with donkey secondary antibodies containing Alexa Fluor fluorophores (Invitrogen) for 
2 h at 4 °C and treated with DAPI. Imaging was performed on a Nikon A1Rsi confocal 
microscope or Leica DMI4000 microscope. Quantification was done with manual counting. 
Assembly of SC-β cells and ECs in suspension 
 
Human umbilical vein endothelial cells (HUVECs) were purchased form Lonza (C2519A) and 
cultured in EGM-2 media (Lonza; CC-3162). HUVECs and Stage 6 clusters containing SC-β 
cells were dispersed with TripLE Express and plated into a 6-well plate on an Orbi-Shaker at 
100 rpm. Two conditions were tested: 3 × 106 Stage 6 cells only (control) and 2.5 × 106 Stage 6 
cells mixed with 0.5 × 106 HUVECs. Cells were cultured in a media of 90% ESFM and 10% 
EGM-2. The presence of these cell types was assessed after 48 h by dispersion and plating into a 
96-well plate followed by immunostaining. 
Assembly of SC-β cells and ECs on tissue culture plastic 
HUVECs and Stage 6 clusters containing SC-β cells were dispersed with TripLE Express and 
plated (1 × 105 cells each) into a 96-well plate pre-coated with diluted (1:80) Matrigel in MCDB 
131. This low concentration of Matrigel will not form a three-dimensional gel like undiluted 
Matrigel, instead providing a thin coating that promotes two-dimensional cell attachment and 




were fixed with 4% paraformaldehyde for immunostaining assessment of both cell types. 
Assembly was quantified by manual counting of all C-peptide+ cells from three separate 
immunostained images of three separate attempted assemblies. 
Assembly of SC-β cells and ECs on a slab of Matrigel hydrogel 
Cold Matrigel (Fisher; 354277; 60 μL), which is qualified for stem cell culture and not growth 
factor reduced, was transferred into 96-well plates and then incubated at 37 °C for 1 h to create 
gel slabs. After this time, HUVECs and Stage 6 clusters containing SC-β cells were dispersed 
with TripLE Express and plated on top of the gel slabs over a range of cell numbers (0.5–
2 × 105 Stage 6 and 0–1.5 × 105 HUVECs). Cells were cultured in a media of 90% ESFM and 
10% EGM-2. After 24 h, the cells were fixed with 4% paraformaldehyde for immunostaining 
assessment of both cell types. Assembly was quantified by manual counting of all C-peptide+ 
cells from three separate immunostained images of three separate assemblies. 
 
Viability Assessment 
Qualitative assessment of viability was performed using the Live/Dead Viability/Cytotoxicity Kit 
(Molecular Probes; L3224). Quantitative assessment of viability was performed by staining cells 





Glucose-stimulated insulin secretion assay 
This assay was performed by first washing cells twice with KRB buffer (128 mM NaCl, 5 mM 
KCl, 2.7 mM CaCl2 1.2 mM MgSO4, 1 mM Na2HPO4, 1.2 mM KH2PO4, 5 mM NaHCO3, 10 mM 
HEPES (Gibco; 15630–080), and 0.1% BSA) and equilibrating cells in 2 mM glucose KRB for a 
1 h. The supernatant was removed and replaced with fresh 2 mM glucose KRB, discarding the 
old KRB solution. Assemblies were incubated for 1 h, the supernatant removed and replaced 
with fresh 20 mM glucose KRB, retaining the old KRB solution. The assemblies were incubated 
for 1 h, the supernatant removed and retained. Insulin concentration with the retained KRB 
supernatant was quantified with a Human Insulin ELISA (ALPCO; 80-INSHU-E10.1). Secretion 
was normalized to cell counts by single-cell dispersing assemblies with 10-min TrypLE Express 
treatment and quantifying viable cell count with a Vi-Cell XR instrument. 
Real-time PCR 
 
The RNeasy Mini Kit (Qiagen; 74016) with DNase treatment (Qiagen; 79254), was used to 
extract RNA from cell assemblies, hESCs, Stage 6 aggregates, and human islets purchased from 
Prodo Labs. The High Capacity cDNA Reverse Transcriptase Kit (Applied Biosystems; 
4368814) was used to make cDNA for gene expression measurements. Real-time PCR was 
performed with a StepOnePlus (Applied Biosystems) instrument using PowerUp SYBR Green 
Master Mix (Applied Biosystems; A25741). Analysis was performed using Δ Δ Ct methodology 
and normalization to TBP. The following primer pairs used: CAATGCCACGCTTCTGC, 
TTCTACACACCCAAGACCCG; PDX1, CGTCCGCTTGTTCTCCTC, 




AACAACAGCCTGCCACCTTA; NKX6-1, CCGAGTCCTGCTTCTTCTTG, 
ATTCGTTGGGGATGACAGAG; CHGA, TGACCTCAACGATGCATTTC, 
CTGTCCTGGCTCTTCTGCTC; NEUROD1, ATGCCCGGAACTTTTTCTTT, 
CATAGAGAACGTGGCAGCAA; NKX2-2, GGAGCTTGAGTCCTGAGGG, 
TCTACGACAGCAGCGACAAC; GCK, ATGCTGGACGACAGAGCC, 
CCTTCTTCAGGTCCTCCTCC; MAFB, CATAGAGAACGTGGCAGCAA, 
ATGCCCGGAACTTTTTCTTT; SOX9, GATTAGCACACTGATCACACGA, 
TTAACCCTCTTCAGAGCAAGC; KRT19, AGGATGCTGAAGCCTGGTT, 
GGTCAGTAACCTCGGACCTG 
Statistical Analysis 
GraphPad Prism was used to determine statistical significance using two-sided unpaired and 
paired t-tests correcting for multiple comparisons using the Holm-Sidak method. Data is 









Figure B.1. Generation of SC-β cell aggregates. 
 
A. Schematic diagram of differentiation process, illustrating cell fate changes to generate SC-β 
cells. The entire procedure is done in cellular aggregates.  
B. Image of spinner flask approach used to grow and differentiate hESCs to SC-β cells. C. 
Micrograph of Stage 6 clusters stained with dithizone, a dye that stains β cells red, imaged under 




D. Immunostaining of Stage 6 cluster sectioned and stained for C-peptide, which is produced by 
β cells, and glucagon, which is produced by α cells. Both primary and secondary antibodies were 
used for the image on the left but only secondary antibodies for the image on the right. These 
images were taken with the same settings. Scale bar = 100 μm.  
E. Immunostaining of dispersed Stage 6 clusters (left) and ECs (right) plated for assessment for 
CD31, an EC marker. These images were taken with the same settings. Scale bar = 100 μm.  
F. Micrographs of unstained reaggregated Stage 6 clusters with or without the addition of ECs 
after 24 h. Scale bar = 400 μm.  
G. Immunostaining of Stage 6 clusters reaggregated with ECs after 24 h then dispersed and 
plated 24 h for assessment. Scale bar = 150 μm. DE, definitive endoderm; PGT, primitive gut 
tube; PP1, pancreatic progenitor 1; PP2, pancreatic progenitor 2; EP, endocrine progenitor; AA, 
activin A; CHIR, CHIR9901; KGF, keratinocyte growth factor; RA, retinoic acid; Y, Y27632; 
LDN, LDN193189; PdbU, phorbol 12,13-dibutyrate; T3, triiodothyronine; Alk5i, Alk5 inhibitor 
type II; ESFM, enriched serum-free medium. (For interpretation of the references to colour in 






Figure B.2. ECs and SC-β cells assemble on top of Matrigel hydrogel but not tissue culture 
plastic. 
A. Immunostaining of Stage 6 clusters mixed with ECs and plated on tissue culture plastic for 
assembly after 24 h. Scale bar = 150 μm.  
B. Quantification of the fraction of C-peptide+ cells in contact with CD31+ cells using the tissue 




C. Bright field micrographs of varying ratios of ECs and SC-β cells plated on a slab of Matrigel 
hydrogel for assembly after 24 h. Scale bar = 400 μm.  
D. En face image of immunostained organoid produced with a 3:1 ratio of SC-β cells and ECs 
after 24 h. Scale bar = 100 μm.  
E. Quantification of the fraction of C-peptide+ cells in contact with CD31+ cells after 24 h using 
the hydrogel approach. n = 3. 
 
 
Figure B.3. Confocal image construction of islet organoid  
 
Islet organoid was produced with 3:1 ratio of SC-β cells and ECs after 24 h. Tilted view is 







Figure B.4. Viability assessment of ECs and SC-β cells assembly formed on Matrigel. 
A. En face image of organoids stained with viability dye indicating live (green) and dead (red) 
cells. Scale bar = 100 μm.  
B. Quantification of the fraction of DTZ+ cells, marking the SC-β cell population, that are viable 
as assessed by trypan blue staining. p > 0.05 by two-way unpaired t-test. n = 3.  
C. Quantification of the fraction of DTZ- cells that are viable as assessed by trypan blue staining. 
n.s. p > 0.05 by two-way unpaired t-test. n = 3. (For interpretation of the references to colour in 






Figure B.5. Glucose-stimulated insulin secretion assay of EC and SC-β cell 
assembly 
Assembly formed on Matrigel. 24 h after (left) compared to Stage 6 aggregates 
containing SC-β cells without ECs (right). **p < 0.01 by two-way paired t-test comparing 





Figure B.6. Marker analysis of EC and SC-β cell assembly formed on Matrigel 
A. Ten genes associated with the β cells and the pancreas were measured, comparing the 




containing SC-β cells without ECs (n = 4), and human islets (n = 3). n.s. p > 0.05, 
*p < 0.05, **p < 0.01, and ***p < 0.001 by two-way unpaired t-test.  
B. En face image of immunostained organoid. CP = C-Peptide. Scale bar = 100 μm. 
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